{"content":"<li class=\"n-box-item date-title\" data-end=\"1502164799\" data-start=\"1502078400\" data-txt=\"Monday, December 23, 2019\">Monday, August  7, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3286565\" data-ts=\"1502149811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMRN\" target=\"_blank\">BMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286565-biomarin-prices-450m-convertible-debt-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioMarin prices $450M convertible debt offering</a></h4><ul>   <li>BioMarin Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a>) has <a href=\"https://seekingalpha.com/pr/16908952-biomarin-announces-offering-450-million-0_599-percent-senior-subordinated-convertible-notes\" target=\"_blank\">priced its $450M debt offering</a> with plans to sell that amount in 0.599% senior subordinated convertible notes due 2024.</li>    <li>Underwriters have a 13-day option to buy up to an addition $45M worth. The company will use most of the net proceeds to settle some or all of its 0.75% senior subordinated convertible notes due October 2018.</li>    <li>Initial conversion rate for the notes will be 8.0212 shares of common stock per $1,000 principal, equivalent to a $124.67 per-share price. Shares closed today at $89.05.</li>    <li>Shares are <font color='red'>down 2.9%</font> after hours at last trade.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3286396-biomarin-launches-450-convertible-debt-offering-shares-ease-2-percent-hours\" target=\"_blank\">BioMarin launches $450 convertible debt offering; shares ease 2% after hours</a> (Aug. 07 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286565\" data-linked=\"BioMarin prices $450M convertible debt offering\" data-tweet=\"$BMRN - BioMarin prices $450M convertible debt offering https://seekingalpha.com/news/3286565-biomarin-prices-450m-convertible-debt-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3286565-biomarin-prices-450m-convertible-debt-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286562\" data-ts=\"1502148471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SITC\" target=\"_blank\">SITC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286562-ddr-prices-350m-in-unsecured-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DDR prices $350M in unsecured debt</a></h4><ul>   <li>DDR (<a href=\"http://seekingalpha.com/symbol/DDR\" target=\"_blank\">DDR</a> <font color='green'>+1.8%</font>) has <a href=\"https://seekingalpha.com/pr/16908916-ddr-prices-350-million-offering-3_900-percent-senior-unsecured-notes\" target=\"_blank\">priced a $350M offering of debt</a>.</li>    <li>The company will offer that amount in 3.9% senior unsecured notes due 2024, at 99.703% of principal (giving a yield to maturity of 3.949%).</li>    <li>It will use net proceeds to redeem all $300M of its 7.875% notes due 2020.</li>    <li>The offering's expected to close Aug. 16; Citigroup Global Markets, Goldman Sachs, U.S. Bancorp Investments and J.P. Morgan Securities are joint book-runners.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286562\" data-linked=\"DDR prices $350M in unsecured debt\" data-tweet=\"$SITC - DDR prices $350M in unsecured debt https://seekingalpha.com/news/3286562-ddr-prices-350m-in-unsecured-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3286562-ddr-prices-350m-in-unsecured-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286557\" data-ts=\"1502145410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALB\" target=\"_blank\">ALB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286557-albemarle-slips-after-hitting-all-time-high-in-todays-trade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Albemarle slips after hitting all-time high in today&#39;s trade</a></h4><ul>     <li>Albemarle (NYSE:<a href='https://seekingalpha.com/symbol/ALB' title='Albemarle Corporation'>ALB</a>) <font color='red'>-3.5%</font>&nbsp;AH despite reporting better than expected <a href=\"https://seekingalpha.com/news/3286533-albemarle-beats-0_02-beats-revenue\" target=\"_blank\">Q2 earnings</a> and in-line revenues that were 10% higher than in the prior-year quarter.</li>     <li>Q2 sales in ALB's lithium and advanced materials business totaled $318M, up 36% Y/Y, primarily because of favorable pricing impacts and increased sales volumes, but sales of bromine specialties fell 1.4% to $204M, mostly due to lower pricing impacts and unfavorable currency exchange impacts.</li>     <li>ALB issues in-line guidance for FY 2017, seeing EPS of $4.20-$4.40 vs. $4.36 analyst consensus estimate and revenues of $2.9B-$3.05B vs. $2.95B consensus.</li>     <li>ALB hit an all-time high in today's regular trading after gaining 43% YTD, and Josh Brown praised the stock on CNBC today as his <a href=\"https://www.cnbc.com/2017/08/07/trader-albemarle-is-breaking-out.html\" target=\"_blank\">preferred way to play the electric vehicle market</a>, saying \"this thing is breaking out... [the] trend looks phenomenal.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286557\" data-linked=\"Albemarle slips after hitting all-time high in today&#39;s trade\" data-tweet=\"$ALB - Albemarle slips after hitting all-time high in today&#39;s trade https://seekingalpha.com/news/3286557-albemarle-slips-after-hitting-all-time-high-in-todays-trade?source=tweet\" data-url=\"https://seekingalpha.com/news/3286557-albemarle-slips-after-hitting-all-time-high-in-todays-trade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286554\" data-ts=\"1502143908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THC\" target=\"_blank\">THC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286554-tenet-healthcareminus-11-after-q2-miss-on-weak-admissions-deep-guidance-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenet Healthcare -11% after Q2 miss on weak admissions, deep guidance cut</a></h4><ul>     <li>Tenet Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a>) <font color='red'>-11.1%</font>&nbsp;AH after reporting a larger than expected <a href=\"https://seekingalpha.com/news/3286433-tenet-healthcare-misses-0_02-misses-revenue\" target=\"_blank\">Q2 loss</a> and cutting FY 2017 guidance below Wall Street expectations.</li>     <li>THC now sees full-year EPS of $0.69-$0.99 from its earlier outlook for $1.05-$1.20 and below the $1.20 analyst consensus estimate, on revenues of $19.1B-$19.4B from its prior view of $19.7B-$20.1B and below the $19.7B consensus.</li>     <li>THC says its full-year outlook is hurt by the sale of its Houston-based assets announced last quarter, lower patient volumes and lower than expected revenue from its Conifer unit.</li>     <li>For Q2, THC says its adjusted admissions on a same-hospital basis, which include patients who stay in the hospital overnight and those treated on an outpatient basis, fell 1.4% Y/Y.</li>     <li>\"We are not surprised by these results and view the admissions growth headwinds facing the hospital sector as longer-term issues that <a href=\"https://www.reuters.com/article/us-tenet-healthcare-results-idUSKBN1AN2DS\" target=\"_blank\">will not be solved in the coming quarters</a>,\" Piper Jaffray analyst Sarah James says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286554\" data-linked=\"Tenet Healthcare -11% after Q2 miss on weak admissions, deep guidance cut\" data-tweet=\"$THC - Tenet Healthcare -11% after Q2 miss on weak admissions, deep guidance cut https://seekingalpha.com/news/3286554-tenet-healthcareminus-11-after-q2-miss-on-weak-admissions-deep-guidance-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3286554-tenet-healthcareminus-11-after-q2-miss-on-weak-admissions-deep-guidance-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286552\" data-ts=\"1502143395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCMI\" target=\"_blank\">NCMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286552-national-cinemediaminus-2_8-q2-revenue-declines-misses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National CineMedia -2.8% as Q2 revenue declines, misses</a></h4><ul>   <li>National CineMedia (<a href=\"http://seekingalpha.com/symbol/NCMI\" target=\"_blank\">NCMI</a> <font color='red'>-2.8%</font>) is another <font color='red'>2.5% lower</font> aftermarket following <a href=\"https://seekingalpha.com/news/3286417-national-cinemedia-misses-0_03-misses-revenue\" target=\"_blank\">Q2 earnings</a> that missed on double-digit revenue declines as theater attendance fell.</li>    <li>Revenues fell nearly 16% and OIBDA dropped 28.8%, to $42.3M. Operating income dropped 3.9! to $28.3M.</li>    <li>Total screens increased 0.7% to 20,623; founding member screens declined to 16,716 from 17,028, and Digital Content Network Screens were at 20,033, down from 20,061.</li>    <li>Total attendance fell to 160M from 172.2M; founding member attendance slipped to 132.5M from 145.9M.</li>    <li>&ldquo;The second quarter completed a challenging first half of 2017, but the second half of 2017 is shaping up nicely so far with the third quarter pacing ahead of last year,\" says CEO Andy England.</li>    <li>It's reaffirming full-year guidance (including impact of an every-five-years 8% hike in theater access fees) for revenue declining from 1-6% ($422M-$442M, vs. consensus for $430.1M), and OIBDA dropping 6-12% Y/Y (to $202M-$217M, vs. consensus for $208.3M).</li>    <li>It expects $18M-$20M in integration payments from Cinemark and AMC associated with Rave Theatres and Carmike Theatres.</li>     <li><a href=\"https://seekingalpha.com/pr/16908699-national-cinemedia-inc-reports-results-fiscal-second-quarter-2017\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3286552\" data-linked=\"National CineMedia -2.8% as Q2 revenue declines, misses\" data-tweet=\"$NCMI - National CineMedia -2.8% as Q2 revenue declines, misses https://seekingalpha.com/news/3286552-national-cinemediaminus-2_8-q2-revenue-declines-misses?source=tweet\" data-url=\"https://seekingalpha.com/news/3286552-national-cinemediaminus-2_8-q2-revenue-declines-misses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286545\" data-ts=\"1502142034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286545-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a> <font color='green'>+52.2%</font>. <a href='https://seekingalpha.com/symbol/CUTR' title='Cutera, Inc.'>CUTR</a> <font color='green'>+16.5%</font>. <a href='https://seekingalpha.com/symbol/MDCA' title='MDC Partners Inc.'>MDCA</a> <font color='green'>+12.4%</font>. <a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a> <font color='green'>+10.6%</font>. <a href='https://seekingalpha.com/symbol/MTW' title='Manitowoc Company, Inc.'>MTW</a> <font color='green'>+9.3%</font>.</li>     <li><b>Top losers:</b> DEPO <font color='red'>-10.9%</font>. <a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='red'>-10.1%</font>. <a href='https://seekingalpha.com/symbol/PAGP' title='Plains GP Holdings, LP'>PAGP</a> <font color='red'>-9.8%</font>. <a href='https://seekingalpha.com/symbol/RUN' title='Sunrun'>RUN</a> <font color='red'>-9.3%</font>. <a href='https://seekingalpha.com/symbol/PAA' title='Plains All American Pipeline, L.P.'>PAA</a> <font color='red'>-8.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286545\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$FGEN $CUTR $MDCA - After Hours Gainers / Losers https://seekingalpha.com/news/3286545-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3286545-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286544\" data-ts=\"1502141973\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTW\" target=\"_blank\">MTW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286544-manitowocplus-9-after-easy-q2-earnings-beat-improved-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Manitowoc +9% after easy Q2 earnings beat, improved guidance</a></h4><ul>     <li>Manitowoc (NYSE:<a href='https://seekingalpha.com/symbol/MTW' title='Manitowoc Company, Inc.'>MTW</a>) <font color='green'>+9.3%</font>&nbsp;AH after reporting a big <a href=\"https://seekingalpha.com/news/3286467-manitowoc-beats-0_09-misses-revenue\" target=\"_blank\">Q2 earnings</a> beat along with revenues that fell 14% Y/Y to $394M from $457M a year ago but nevertheless exceeded analyst estimates.</li>     <li>MTW says most of the sales decline was due to lower crawler crane shipments in the Americas as it shipped a \"significant volume\" of the items in the prior year, as well as lower rough terrain crane shipments in the Americas and in the Middle East due to continued weakness in oil and gas market demand.</li>     <li>Q2 orders of $379.5M, which included the initial production order related to the U.S. Army contract, were up 9% Y/Y, and backlog of $491M at the end of the quarter was up 25% from the year-ago quarter ending backlog of $393.5M.</li>     <li>MTW also raises its FY 2017 guidance to a 5%-7% Y/Y decline vs. a prior outlook for an 8%-10% drop, and adjusted EBITDA of $59M-$69M from its previous forecast of $41M-$59M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286544\" data-linked=\"Manitowoc +9% after easy Q2 earnings beat, improved guidance\" data-tweet=\"$MTW - Manitowoc +9% after easy Q2 earnings beat, improved guidance https://seekingalpha.com/news/3286544-manitowocplus-9-after-easy-q2-earnings-beat-improved-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3286544-manitowocplus-9-after-easy-q2-earnings-beat-improved-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286526\" data-ts=\"1502139785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENDP\" target=\"_blank\">ENDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286526-endo-to-settle-u-s-mesh-product-liability-claims-775m-added-to-q2-accrual-shares-down-3-after\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endo to settle U.S. mesh product liability claims; $775M added to Q2 accrual; shares down 3% after hours</a></h4><ul><li>Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) slips&nbsp;<font color='red'>3%</font>&nbsp;after hours on robust volume on the heels of its <a href=\"https://seekingalpha.com/pr/16908822-endo-announces-agreements-resolve-virtually-known-u-s-mesh-product-liability-claims\" target=\"_blank\">announcement </a>that it has reached agreement to resolve virtually all known U.S. mesh product liability claims and is in discussions to resolve them all at reasonable valuations.</li><li>Under the terms of agreements, it will make installment payments beginning in Q4 and continuing through Q4 2019. In Q2, it will increase its liability accrual by $775M which should cover ~22K U.S. cases and all known international product liability claims and other mesh-related matters.</li><li>CEO Paul Campanelli says, \"Beginning in the second quarter of 2017, we aggressively executed a settlement strategy in connection with Endo's mesh litigation. We believe it is a very important milestone for Endo to have reached agreements to resolve virtually all known&nbsp;U.S.&nbsp;mesh product liability claims. While it remains possible that additional claims will be filed, we believe today's announcement will assist most mesh claimants to move forward with their lives and will permit Endo to move forward with an even greater focus on executing against our core strategic priorities.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3286526\" data-linked=\"Endo to settle U.S. mesh product liability claims; $775M added to Q2 accrual; shares down 3% after hours\" data-tweet=\"$ENDP - Endo to settle U.S. mesh product liability claims; $775M added to Q2 accrual; shares down 3% after hours https://seekingalpha.com/news/3286526-endo-to-settle-u-s-mesh-product-liability-claims-775m-added-to-q2-accrual-shares-down-3-after?source=tweet\" data-url=\"https://seekingalpha.com/news/3286526-endo-to-settle-u-s-mesh-product-liability-claims-775m-added-to-q2-accrual-shares-down-3-after\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286500\" data-ts=\"1502138757\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESNT\" target=\"_blank\">ESNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286500-capital-raise-essent-group-shares-down-1_2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capital raise at Essent Group; shares down 1.2%</a></h4><ul><li>The <a href=\"https://seekingalpha.com/pr/16908842-essent-group-ltd-announces-launch-public-offering\" target=\"_blank\">offering is for </a>7M common shares, with underwriter greenshoe of up to 750K shares.</li><li><a href='https://seekingalpha.com/symbol/ESNT' title='Essent Group Ltd.'>ESNT</a>&nbsp;<font color='red'>-1.2%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3286500\" data-linked=\"Capital raise at Essent Group; shares down 1.2%\" data-tweet=\"$ESNT - Capital raise at Essent Group; shares down 1.2% https://seekingalpha.com/news/3286500-capital-raise-essent-group-shares-down-1_2?source=tweet\" data-url=\"https://seekingalpha.com/news/3286500-capital-raise-essent-group-shares-down-1_2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286499\" data-ts=\"1502138695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FGEN\" target=\"_blank\">FGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286499-fibrogen-misses-0_01-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FibroGen misses by $0.01, misses on revenue</a></h4><ul><li>FibroGen (NASDAQ:<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a>): Q2 EPS of -$0.48 <font color='red'>misses by $0.01</font>.</li><li>Revenue of $29M (-67.5% Y/Y) <font color='red'>misses by $5.32M</font>.</li><li>Shares <font color='green'>+46.7%</font>.</li><li><a href='https://seekingalpha.com/pr/16908836-fibrogen-reports-second-quarter-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3286499\" data-linked=\"FibroGen misses by $0.01, misses on revenue\" data-tweet=\"$FGEN - FibroGen misses by $0.01, misses on revenue https://seekingalpha.com/news/3286499-fibrogen-misses-0_01-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3286499-fibrogen-misses-0_01-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286489\" data-ts=\"1502138288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATSG\" target=\"_blank\">ATSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286489-air-transport-services-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Air Transport Services beats by $0.02, beats on revenue</a></h4><ul><li>Air Transport Services (NASDAQ:<a href='https://seekingalpha.com/symbol/ATSG' title='Air Transport Services Group, Inc'>ATSG</a>): Q2 EPS of $0.21 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $253.21M (+43.4% Y/Y) <font color='green'>beats by $17.02M</font>.</li><li>Shares <font color='green'>+5.01%</font>.</li><li><a href='https://seekingalpha.com/pr/16908831-atsg-growth-continues-midsize-freighter-leasing-expands'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3286489\" data-linked=\"Air Transport Services beats by $0.02, beats on revenue\" data-tweet=\"$ATSG - Air Transport Services beats by $0.02, beats on revenue https://seekingalpha.com/news/3286489-air-transport-services-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3286489-air-transport-services-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286486\" data-ts=\"1502138146\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASRT\" target=\"_blank\">ASRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286486-depomed-q2-top-line-down-14-nucynta-sales-down-11-non-gaap-earnings-down-61-guidance-lowered\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Depomed Q2 top line down 14%; Nucynta sales down 11%; non-GAAP earnings down 61%; guidance lowered; shares down 6% after hours</a></h4><ul><li>Depomed (DEPO)<a href=\"https://seekingalpha.com/pr/16908663-depomed-announces-second-quarter-2017-financial-results\" target=\"_blank\"> Q2 results</a> ($M): Revenues: 100.5 (-13.9%); Nucynta products: 63.9 (-11.1%); Gralise: 18.1 (-23.9%).</li><li>Net Loss: (26.7) (-154.3%); Non-GAAP Net Income: 5.4 (-61.2%); Loss/Share: (0.43) (-152.9%); Non-GAAP EPS: 0.08 (-57.9%).</li><li><strong>2017 Guidance</strong>: Revenues: $395M - 410M from $405M - 425M; Non-GAAP EBITDA: $107M - 117M from $120M - 130M.</li><li>Neurology salesforce to be increased to 90 from 40 effective September 1.</li><li>Shares are down&nbsp;<font color='red'>6%</font>&nbsp;after hours on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286486\" data-linked=\"Depomed Q2 top line down 14%; Nucynta sales down 11%; non-GAAP earnings down 61%; guidance lowered; shares down 6% after hours\" data-tweet=\"$ASRT - Depomed Q2 top line down 14%; Nucynta sales down 11%; non-GAAP earnings down 61%; guidance lowered; shares down 6% after hours https://seekingalpha.com/news/3286486-depomed-q2-top-line-down-14-nucynta-sales-down-11-non-gaap-earnings-down-61-guidance-lowered?source=tweet\" data-url=\"https://seekingalpha.com/news/3286486-depomed-q2-top-line-down-14-nucynta-sales-down-11-non-gaap-earnings-down-61-guidance-lowered\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286476\" data-ts=\"1502137844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOA\" target=\"_blank\">BIOA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286476-bioamberminus-9-on-news-of-public-offering-follows-todays-35-plunge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioAmber -9% on news of public offering follows today&#39;s 35% plunge</a></h4><ul>     <li>BioAmber (<a href='https://seekingalpha.com/symbol/BIOA' title='BioAmber'>OTC:BIOA</a>) <font color='red'>-9.1%</font> AH after launching a <a href=\"https://seekingalpha.com/pr/16908656-bioamber-inc-announces-underwritten-offering-common-stock-warrants\" target=\"_blank\">public stock offering</a> of unspecified size, with each common share to be sold together in a  fixed combination with a warrant to purchase additional common shares.</li>     <li>BIOA says it plans to use the proceeds for working capital and general corporate purposes.</li>     <li>Shares fell 35% in regular trading after the company's <a href=\"https://www.sec.gov/Archives/edgar/data/1534287/000156459017015516/bioa-10q_20170630.htm\" target=\"_blank\">10-Q</a> warned that the Trump administration potentially could discontinue U.S. government policies that would help pay for its planned $500M facility to produce 200K metric tons/year of bio-succinic acid.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286476\" data-linked=\"BioAmber -9% on news of public offering follows today&#39;s 35% plunge\" data-tweet=\"$BIOA - BioAmber -9% on news of public offering follows today&#39;s 35% plunge https://seekingalpha.com/news/3286476-bioamberminus-9-on-news-of-public-offering-follows-todays-35-plunge?source=tweet\" data-url=\"https://seekingalpha.com/news/3286476-bioamberminus-9-on-news-of-public-offering-follows-todays-35-plunge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286461\" data-ts=\"1502137602\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286461-twilio-beats-q2-and-guidance-estimates-sharesplus-11_6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twilio beats Q2 and guidance estimates; shares +11.6%</a></h4><ul><li>        Twilio (NYSE:<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>) reports Q2 results with revenue and EPS beats. Base revenue, which excludes sales from large customer accounts without a 12-month minimum contract, was $87.6M, up 55% from the prior year&rsquo;s quarter and 9% sequentially.</li><li>                  Active customer accounts numbered 43,431 In Q2 compared to about 31K last year.    </li><li>               Twilio reported $92M in cash and equivalents at the end of the quarter.&nbsp;</li><li>               Q3 guidance: revenue, $91M to $93M (consensus:$89.69M); base revenue, $86.5M to $87.5M; loss per share, $0.08 to $0.07 (consensus: $0.08).&nbsp;</li><li>               Full year guidance: revenue, $371M to $375M (consensus: $359.79M); base revenue, $348.5M to $350.5M; loss per share, $0.24 to $0.22 (consensus: $0.29).&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16908691-twilio-announces-second-quarter-2017-results\" target=\"_blank\">Press release</a>&nbsp;</li><li>Twilio shares are&nbsp;<font color='green'>up 11.63%</font>&nbsp;aftermarket. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3286385-twilio-beats-0_06-beats-revenue\" target=\"_blank\">Twilio beats by $0.06, beats on revenue</a> (Aug. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286461\" data-linked=\"Twilio beats Q2 and guidance estimates; shares +11.6%\" data-tweet=\"$TWLO - Twilio beats Q2 and guidance estimates; shares +11.6% https://seekingalpha.com/news/3286461-twilio-beats-q2-and-guidance-estimates-sharesplus-11_6?source=tweet\" data-url=\"https://seekingalpha.com/news/3286461-twilio-beats-q2-and-guidance-estimates-sharesplus-11_6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286452\" data-ts=\"1502137454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286452-mannkind-q2-afrezza-sales-1_5m-treprostinil-ind-on-tap-in-q4-shares-off-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MannKind Q2 Afrezza sales: $1.5M, treprostinil IND on tap in Q4; shares off 1% after hours</a></h4><ul><li>MannKind (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) <a href=\"https://seekingalpha.com/pr/16908705-mannkind-corporation-reports-2017-second-quarter-financial-results\" target=\"_blank\">Q2 results</a> ($M): Revenues: 2.2; Afrezza sales: 1.5; Net Loss: (35.3) (-17.7%); Loss/Share: (0.35) (-6.1%); Quick Assets: 43.4 (+89.5%).</li><li>Afrezza product shipped to wholesale and retail channels but not yet recognized: $2.6M.</li><li>Positive pre-IND meeting with FDA in June re treprostinil Technosphere for the treatment of pulmonary arterial hypertension. IND to be filed by year-end.</li><li>Shares are down&nbsp;<font color='red'>1%</font>&nbsp;after hours on modest volume.</li><li><strong>Update</strong>: The company plans to voluntarily delist its shares from the Tel Aviv Stock Exchange.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286452\" data-linked=\"MannKind Q2 Afrezza sales: $1.5M, treprostinil IND on tap in Q4; shares off 1% after hours\" data-tweet=\"$MNKD - MannKind Q2 Afrezza sales: $1.5M, treprostinil IND on tap in Q4; shares off 1% after hours https://seekingalpha.com/news/3286452-mannkind-q2-afrezza-sales-1_5m-treprostinil-ind-on-tap-in-q4-shares-off-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3286452-mannkind-q2-afrezza-sales-1_5m-treprostinil-ind-on-tap-in-q4-shares-off-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286410\" data-ts=\"1502136794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOK\" target=\"_blank\">MYOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286410-myokardia-readies-3_5m-share-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MyoKardia readies 3.5M-share stock offering</a></h4><ul><li>MyoKardia (NASDAQ:<a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a>) launches a <a href=\"https://seekingalpha.com/pr/16908653-myokardia-announces-proposed-public-offering-common-stock\" target=\"_blank\">public offering </a>of 3.5M shares of common stock. Underwriters over-allotment will be an additional 525K shares. Price and terms have yet to be announced.</li><li>Net proceeds will fund R&amp;D, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286410\" data-linked=\"MyoKardia readies 3.5M-share stock offering\" data-tweet=\"$MYOK - MyoKardia readies 3.5M-share stock offering https://seekingalpha.com/news/3286410-myokardia-readies-3_5m-share-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3286410-myokardia-readies-3_5m-share-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286399\" data-ts=\"1502136623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LC\" target=\"_blank\">LC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286399-lendingclub-up-7-after-revenue-tops-guidance-impresses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LendingClub up 7% after revenue tops; guidance impresses</a></h4><ul><li>Q2 adjusted loss per share of $0.01 vs. a loss of $0.02 in Q1, and $0.09 a year ago. Adjusted EBITDA of $4.5M vs. $200K in Q1, and loss of $29.1M a year ago.</li><li>Originations of $2.15B up 10% Q/Q, 10% Y/Y.</li><li>Full-year revenue is seen at $585M-$600M, with adjusted EBITDA of $50M-$58M - the Street is at $585M for revenue, $53M for adjusted EBTIDA. Q3 revenue is seen at $154M-$159M, with adjusted EBITDA of $18M-$22M.</li><li><a href=\"http://ir.lendingclub.com\" target=\"_blank\">Conference call at 5 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3286384-lendingclub-eps-line-beats-revenue\" target=\"_blank\">LendingClub EPS in-line, beats on revenue</a> (Aug. 7)</li><li><a href='https://seekingalpha.com/symbol/LC' title='LendingClub Corporation'>LC</a>&nbsp;<font color='green'>+7.15%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3286399\" data-linked=\"LendingClub up 7% after revenue tops; guidance impresses\" data-tweet=\"$LC - LendingClub up 7% after revenue tops; guidance impresses https://seekingalpha.com/news/3286399-lendingclub-up-7-after-revenue-tops-guidance-impresses?source=tweet\" data-url=\"https://seekingalpha.com/news/3286399-lendingclub-up-7-after-revenue-tops-guidance-impresses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286396\" data-ts=\"1502136602\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMRN\" target=\"_blank\">BMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286396-biomarin-launches-450-convertible-debt-offering-shares-ease-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioMarin launches $450 convertible debt offering; shares ease 2% after hours</a></h4><ul><li>BioMarin Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a>) slips<font color='red'> 2%</font>&nbsp;after hours on average volume in response to its <a href=\"https://seekingalpha.com/pr/16908650-biomarin-announces-offering-450-million-senior-subordinated-convertible-notes-due-2024\" target=\"_blank\">proposed offering</a> of $450M aggregate principal amount of senior subordinated convertible notes due 2024.</li><li>Most of the net proceeds will be used to retire some or all of its 0.75% senior subordinated notes due October 2018. The remainder will be used for general corporate purposes.</li><li>Price and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286396\" data-linked=\"BioMarin launches $450 convertible debt offering; shares ease 2% after hours\" data-tweet=\"$BMRN - BioMarin launches $450 convertible debt offering; shares ease 2% after hours https://seekingalpha.com/news/3286396-biomarin-launches-450-convertible-debt-offering-shares-ease-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3286396-biomarin-launches-450-convertible-debt-offering-shares-ease-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286388\" data-ts=\"1502136437\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRAY\" target=\"_blank\">VRAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286388-viewray-beats-0_09-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViewRay beats by $0.09, beats on revenue</a></h4><ul><li>ViewRay (NASDAQ:<a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a>): Q2 EPS of -$0.15 <font color='green'>beats by $0.09</font>.</li><li>Revenue of $0.7M (+133.3% Y/Y) <font color='green'>beats by $0.04M</font>.</li><li>Shares <font color='green'>+1.3%</font>.</li><li><a href='https://seekingalpha.com/pr/16908661-viewray-reports-second-quarter-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3286388\" data-linked=\"ViewRay beats by $0.09, beats on revenue\" data-tweet=\"$VRAY - ViewRay beats by $0.09, beats on revenue https://seekingalpha.com/news/3286388-viewray-beats-0_09-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3286388-viewray-beats-0_09-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286385\" data-ts=\"1502136396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286385-twilio-beats-0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twilio beats by $0.06, beats on revenue</a></h4><ul><li>Twilio (NYSE:<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>): Q2 EPS of -$0.05 <font color='green'>beats by $0.06</font>.</li><li>Revenue of $95.87M (+48.6% Y/Y) <font color='green'>beats by $9.63M</font>.</li><li>Shares <font color='green'>+13%</font>.</li><li><a href='https://seekingalpha.com/pr/16908691-twilio-announces-second-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3286385\" data-linked=\"Twilio beats by $0.06, beats on revenue\" data-tweet=\"$TWLO - Twilio beats by $0.06, beats on revenue https://seekingalpha.com/news/3286385-twilio-beats-0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3286385-twilio-beats-0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286384\" data-ts=\"1502136382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LC\" target=\"_blank\">LC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286384-lendingclub-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LendingClub EPS in-line, beats on revenue</a></h4><ul><li>LendingClub (NYSE:<a href='https://seekingalpha.com/symbol/LC' title='LendingClub Corporation'>LC</a>): Q2 EPS of -$0.01 in-line.</li><li>Revenue of $139.6M (+35.0% Y/Y) <font color='green'>beats by $3.19M</font>.</li><li>Shares <font color='green'>+7.2%</font>.</li><li><a href='https://seekingalpha.com/pr/16908667-lendingclub-reports-second-quarter-full-year-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3286384\" data-linked=\"LendingClub EPS in-line, beats on revenue\" data-tweet=\"$LC - LendingClub EPS in-line, beats on revenue https://seekingalpha.com/news/3286384-lendingclub-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3286384-lendingclub-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286364\" data-ts=\"1502135370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COL\" target=\"_blank\">COL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286364-analysts-generally-cool-to-united-tech-rockwell-collins-combo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts generally cool to United Tech-Rockwell Collins combo</a></h4><ul>     <li>Rockwell Collins (<a href='https://seekingalpha.com/symbol/COL' title='Rockwell Collins, Inc.'>COL</a> <font color='green'>+6.6%</font>) is on track to <a href=\"http://www.marketwatch.com/story/rockwell-collins-shares-on-pace-for-record-high-after-deal-news-2017-08-07\" target=\"_blank\">close at an all-time record high</a> following reports that United Technologies (<a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a> <font color='red'>-2.5%</font>)&nbsp;is working on a deal to buy the aircraft equipment maker (<a href=\"https://seekingalpha.com/news/3286056-rockwell-collins-plus-9_5-percent-report-utx-looking-buyout\" target=\"_blank\">I</a>, <a href=\"https://seekingalpha.com/news/3286326-rockwell-collins-pops-new-report-detailing-united-tech-takeover-interest\" target=\"_blank\">II</a>), but analysts generally are cool to the prospective deal.</li>     <li>A UTX-COL combination &ldquo;would be one of the largest aerospace suppliers globally,&rdquo; with pro forma revenues of ~$38B, and part of UTX&rsquo;s motivation to buy COL would be &ldquo;the incremental pressure on the supply chain from Boeing, both from a price and economics standpoint,&rdquo; analysts at Canaccord say.</li>     <li>While such a deal might make strategic sense, the \"<a href=\"http://www.barrons.com/articles/united-technologies-not-now-please-not-now-1502118049\" target=\"_blank\">timing does not</a>,\" says Wells Fargo analyst Sam Pearlstein; while UTX has long expressed interest in adding avionics, the timing of its interest in COLis \"surprising\" since major airplane makers including Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='green'>+1.1%</font>) are considering moving into avionics and aftermarket, and UTX could have moved to buy COL prior to closing its B/E Aerospace acquisition in April \"such that UTX would not effectively pay the B/E control premium twice (once by COL and again by UTX).\"</li>     <li>COL shareholders would require a <a href=\"https://www.wsj.com/articles/united-technologies-rockwell-collins-deal-too-expensive-to-fly-1502124619\" target=\"_blank\">hefty takeover premium</a> given the company's margins, which are substantially higher than that of UTX, writes <em>Heard On The Street</em>'s Alex Frangos.</li>     <li>J.P. Morgan's Stephen Tusa said earlier that a deal for COL would be a \"<a href=\"https://seekingalpha.com/news/3286232-jpmorgan-comments-potential-utx-col-deal\" target=\"_blank\">mixed event</a>\" for UTX.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286364\" data-linked=\"Analysts generally cool to United Tech-Rockwell Collins combo\" data-tweet=\"$COL $COL $UTX - Analysts generally cool to United Tech-Rockwell Collins combo https://seekingalpha.com/news/3286364-analysts-generally-cool-to-united-tech-rockwell-collins-combo?source=tweet\" data-url=\"https://seekingalpha.com/news/3286364-analysts-generally-cool-to-united-tech-rockwell-collins-combo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286356\" data-ts=\"1502132943\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CANN\" target=\"_blank\">CANN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286356-general-cannabis-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Cannabis reports Q2 results</a></h4><ul><li>General Cannabis (<a href='https://seekingalpha.com/symbol/CANN' title='General Cannabis Corp.'>OTCQX:CANN</a>): Q2 EPS of -$0.05</li><li>Revenue of $0.84M (+18.3% Y/Y)</li><li>Shares <font color='green'>+3.85%</font>.</li><li><a href='https://seekingalpha.com/pr/16908592-general-cannabis-announces-2017-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3286356\" data-linked=\"General Cannabis reports Q2 results\" data-tweet=\"$CANN - General Cannabis reports Q2 results https://seekingalpha.com/news/3286356-general-cannabis-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3286356-general-cannabis-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286354\" data-ts=\"1502132488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286354-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/BITA' title='Bitauto Holdings Limited'>BITA</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/IOTS' title='Adesto Technologies'>IOTS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a> <font color='green'>+12%.</font></li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PNTR' title='Pointer Telocation Ltd.'>PNTR</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/TNAV' title='Telenav, Inc.'>TNAV</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NNDM' title='Nano Dimension Ltd ADR'>NNDM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/DTRM' title='Determine, Inc.'>OTC:DTRM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RBCN' title='Rubicon Technology, Inc.'>RBCN</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286354\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$JRJC $BITA $TCCO - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3286354-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3286354-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286348\" data-ts=\"1502130964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LC\" target=\"_blank\">LC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286348-lendingclub-up-5-on-back-of-ondeck-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LendingClub up 5% on back of OnDeck results</a></h4><ul><li>OnDeck Capital is sporting an&nbsp;<font color='green'>18% gain</font>&nbsp;following its <a href=\"https://seekingalpha.com/news/3286265-ondeck-capital-6-percent-earnings-beat\" target=\"_blank\">Q2 results</a>. Originations were down following a move toward tighter underwriting, but credit metrics improved. With expense savings getting more locked in, management can focus on achieving profitability by year-end.</li><li>LendingClub (NYSE:<a href='https://seekingalpha.com/symbol/LC' title='LendingClub Corporation'>LC</a>) - which reports after the closing bell - is&nbsp;<font color='green'>higher by 5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286348\" data-linked=\"LendingClub up 5% on back of OnDeck results\" data-tweet=\"$LC - LendingClub up 5% on back of OnDeck results https://seekingalpha.com/news/3286348-lendingclub-up-5-on-back-of-ondeck-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3286348-lendingclub-up-5-on-back-of-ondeck-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286346\" data-ts=\"1502130044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286346-energy-materials-top-5-gainers-losers-of-2-20-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:20 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/WRN' title='Western Copper and Gold Corporation'>WRN</a> <font color='green'>+8%</font>.<a href='https://seekingalpha.com/symbol/SHI' title='Sinopec Shanghai Petrochemical Company Limited'>SHI</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SID' title='Companhia Siderurgica Nacional'>SID</a> <font color='green'>+7%</font>.</li>     <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/BAS' title='Basic Energy Services, Inc.'>BAS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BIOA' title='BioAmber'>OTC:BIOA</a> <font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='red'>-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286346\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:20 pm\" data-tweet=\"$EGO $WRN $SHI - Energy/Materials - Top 5 Gainers / Losers as of 2:20 pm https://seekingalpha.com/news/3286346-energy-materials-top-5-gainers-losers-of-2-20-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3286346-energy-materials-top-5-gainers-losers-of-2-20-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286345\" data-ts=\"1502130042\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CXW\" target=\"_blank\">CXW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286345-corecivic-down-5-alongside-geo-group-selloff\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CoreCivic down 5% alongside GEO Group selloff</a></h4><ul><li>GEO Group is&nbsp;<font color='red'>off nearly 8%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3286334-geo-group-7-percent-results-soft-revenue-outlook\" target=\"_blank\">missing Q2 revenue</a> and guiding for light revenues in Q3 and for the full year.</li><li>Fellow private prison operator CoreCivic (NYSE:<a href='https://seekingalpha.com/symbol/CXW' title='CoreCivic, Inc.'>CXW</a>) is&nbsp;<font color='red'>lower by 5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286345\" data-linked=\"CoreCivic down 5% alongside GEO Group selloff\" data-tweet=\"$CXW - CoreCivic down 5% alongside GEO Group selloff https://seekingalpha.com/news/3286345-corecivic-down-5-alongside-geo-group-selloff?source=tweet\" data-url=\"https://seekingalpha.com/news/3286345-corecivic-down-5-alongside-geo-group-selloff\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286343\" data-ts=\"1502129821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ON\" target=\"_blank\">ON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286343-needham-upgrades-on-semi-to-strong-buy-shares-up-6_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham upgrades ON Semi to Strong Buy; shares up 6.5%</a></h4><ul><li>        Needham &amp; Company upgrades ON Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/ON' title='ON Semiconductor Corporation'>ON</a>) from Buy to Strong Buy and increases the price target by $5 to $25.</li><li>               Analyst Rajvindra Gill cites the company&rsquo;s gross margin tailwinds and positioning in the industrial and auto industries.&nbsp;</li><li>               Gill thinks ON can achieve its goal of 40% gross margin by 2020 and expects the company to use its over $600M in FCF to pay off debt.&nbsp;</li><li>               Gill calls the company one of the cheapest semiconductor companies, noting the current 10x 2018 P/E and estimates a real value of 16x.&nbsp;</li><li>               Source:<a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Needham+%26+Company+Upgrades+ON+Semiconductor+%28ON%29+to+Strong+Buy/13175467.html\" target=\"_blank\"> StreetInsider</a>&nbsp;</li><li>               ON Semiconductor shares are&nbsp;<font color='green'>up 6.46%</font>. &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3286343\" data-linked=\"Needham upgrades ON Semi to Strong Buy; shares up 6.5%\" data-tweet=\"$ON - Needham upgrades ON Semi to Strong Buy; shares up 6.5% https://seekingalpha.com/news/3286343-needham-upgrades-on-semi-to-strong-buy-shares-up-6_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3286343-needham-upgrades-on-semi-to-strong-buy-shares-up-6_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286341\" data-ts=\"1502129338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOS\" target=\"_blank\">KOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286341-kosmos-energy-cuts-another-50m-from-2017-capex\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kosmos Energy cuts another $50M from 2017 capex</a></h4><ul>     <li>Kosmos Energy (<a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy'>KOS</a> <font color='green'>+2.4%</font>) swings between gains and losses and now sits at its highs of the day after reporting a narrower than expected <a href=\"https://seekingalpha.com/news/3286134-kosmos-energy-beats-0_01-misses-revenue\" target=\"_blank\">Q2 loss</a> and revenues that more than tripled compared with year-ago levels.</li>     <li>KOS says Q2 oil revenues totaled $136M on sales of 2.9M barrels of oil vs. $46M on 900K barrels in the same quarter of 2016; realized oil revenues, including hedging, were $51.21/bbl of oil sold in Q2 vs. $95.61/bbl sold in the year-ago quarter.</li>     <li>KOS cuts its 2017 capital budget to $100M from $150M, reflecting lower capex requirements in Ghana associated with reduced Jubilee costs and a one-time accrual adjustment in Ghana; the new capex budget is nearly 85% lower than its 2016 capex.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286341\" data-linked=\"Kosmos Energy cuts another $50M from 2017 capex\" data-tweet=\"$KOS - Kosmos Energy cuts another $50M from 2017 capex https://seekingalpha.com/news/3286341-kosmos-energy-cuts-another-50m-from-2017-capex?source=tweet\" data-url=\"https://seekingalpha.com/news/3286341-kosmos-energy-cuts-another-50m-from-2017-capex\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286337\" data-ts=\"1502127773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MET\" target=\"_blank\">MET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286337-rough-debut-for-brighthouse-financial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rough debut for Brighthouse Financial</a></h4><ul><li>In its first day of regular trade since the spin out from MetLife (NYSE:<a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a>), Brighthouse Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/BHF' title='Brighthouse Financial, Inc.'>BHF</a>) is<font color='red'> lower by 5.4%</font>.</li><li>It's getting plenty of sell-side coverage, but little analyst love. In no surprise, Citi's&nbsp;Suneet Kamath - <a href=\"https://seekingalpha.com/news/3275037-metlife-accounting-exaggerates-profitability-citi\" target=\"_blank\">the Street's lone bear </a>on MetLife - rates Brighthouse a Sell, with $50 price target (20% downside).</li><li>Wells Fargo, RBC, KBW, Credit Suisse, and FBR all rate Brighthouse at Neutral (or its equivalent).</li></ul><div class=\"tiny-share-widget\" data-id=\"3286337\" data-linked=\"Rough debut for Brighthouse Financial\" data-tweet=\"$MET $BHF - Rough debut for Brighthouse Financial https://seekingalpha.com/news/3286337-rough-debut-for-brighthouse-financial?source=tweet\" data-url=\"https://seekingalpha.com/news/3286337-rough-debut-for-brighthouse-financial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286334\" data-ts=\"1502126774\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEO\" target=\"_blank\">GEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286334-geo-group-down-7-after-results-soft-revenue-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GEO Group down 7% after results, soft revenue outlook</a></h4><ul><li>Adjusted net income in Q2 was $38.8M or $0.32 per share.</li><li>Adjusted FFO of $74.7M or $0.61 per share compared to $67.7M and $0.61 a year ago. Q2 NOI of $146.5M vs. $138.1M.</li><li>Q3 revenue guidance of $554M-$559M vs. consensus $579M. Q3 AFFO is seen at $0.61-$0.63 per share.</li><li>Q4 revenue guided to $557M-$562M; AFFO per share of $0.63-$0.65.</li><li>Full-year revenue seen at $2.24B vs. $2.29B expected; AFFO per share of $2.50-$2.54.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3286138-geo-group-beats-0_02-misses-revenue\" target=\"_blank\">GEO Group beats by $0.02, misses on revenue</a> (Aug. 7)</li><li><a href='https://seekingalpha.com/symbol/GEO' title='The GEO Group, Inc.'>GEO</a>&nbsp;<font color='red'>-7.15%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3286334\" data-linked=\"GEO Group down 7% after results, soft revenue outlook\" data-tweet=\"$GEO - GEO Group down 7% after results, soft revenue outlook https://seekingalpha.com/news/3286334-geo-group-down-7-after-results-soft-revenue-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3286334-geo-group-down-7-after-results-soft-revenue-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286330\" data-ts=\"1502125759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286330-financials-top-5-gainers-losers-of-1-10-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:10 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ONDK' title='OnDeck Capital'>ONDK</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+7%</font>.<a href='https://seekingalpha.com/symbol/QIWI' title='QIWI plc'>QIWI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/LAND' title='Gladstone Land'>LAND</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BRG' title='Bluerock Residential Growth REIT, Inc.'>BRG</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ABDC' title='Alcentra Capital Corporation'>ABDC</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/PW' title='Power REIT'>PW</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/GEO' title='The GEO Group, Inc.'>GEO</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286330\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:10 PM\" data-tweet=\"$ONDK $YRD $QIWI - Financials - Top 5 Gainers / Losers as of 1:10 PM https://seekingalpha.com/news/3286330-financials-top-5-gainers-losers-of-1-10-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3286330-financials-top-5-gainers-losers-of-1-10-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286326\" data-ts=\"1502125039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COL\" target=\"_blank\">COL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286326-rockwell-collins-pops-after-new-report-detailing-united-tech-takeover-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rockwell Collins pops after new report detailing United Tech takeover interest</a></h4><ul>     <li>Rockwell Collins (<a href='https://seekingalpha.com/symbol/COL' title='Rockwell Collins, Inc.'>COL</a> <font color='green'>+6.6%</font>), already sharply higher, jumps to highs of the day following another report saying United Technologies (<a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a> <font color='red'>-2.6%</font>) has <a href=\"https://www.wsj.com/articles/united-tech-in-takeover-talks-with-rockwell-collins-1502124246\" target=\"_blank\">approached COL for takeover talks</a>.</li>     <li>The <em>WSJ</em> report says UTX made an initial offer of less than $140/share but the two companies are still wrangling over the price of a takeover that would exceed $20B.</li>     <li>COL shares rallied earlier following a Bloomberg report <a href=\"https://seekingalpha.com/news/3286056-rockwell-collins-plus-9_5-percent-report-utx-looking-buyout\" target=\"_blank\">after Friday's close</a> that UTX was weighing a bid for the aircraft component maker.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286326\" data-linked=\"Rockwell Collins pops after new report detailing United Tech takeover interest\" data-tweet=\"$COL $COL $UTX - Rockwell Collins pops after new report detailing United Tech takeover interest https://seekingalpha.com/news/3286326-rockwell-collins-pops-after-new-report-detailing-united-tech-takeover-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3286326-rockwell-collins-pops-after-new-report-detailing-united-tech-takeover-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286317\" data-ts=\"1502124129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286317-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a> <font color='green'>+85%</font>. <a href='https://seekingalpha.com/symbol/ATV' title='Acorn International, Inc.'>ATV</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/NXTM' title='NxStage Medical, Inc.'>NXTM</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/MTNB' title='Matinas Biopharma Holdings, Inc.'>MTNB</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/ONDK' title='OnDeck Capital'>ONDK</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='red'>-58%</font>. <a href='https://seekingalpha.com/symbol/GEMP' title='Gemphire Therapeutics'>GEMP</a> <font color='red'>-47%</font>. <a href='https://seekingalpha.com/symbol/BIOA' title='BioAmber'>OTC:BIOA</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/AFI' title='Armstrong Flooring, Inc.'>AFI</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/PNTR' title='Pointer Telocation Ltd.'>PNTR</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/FLDM' title='Fluidigm Corporation'>FLDM</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/PGEM' title='Ply Gem Holdings'>PGEM</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/III' title='Information Services Group, Inc.'>III</a> <font color='red'>-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286317\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MYOK $ATV $NXTM - Midday Gainers / Losers https://seekingalpha.com/news/3286317-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3286317-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286314\" data-ts=\"1502123899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286314-biocept-preferred-provider-scripps-health-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept a preferred provider with Scripps Health, shares up 6%</a></h4><ul><li>Thinly traded nano cap Biocept (<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='green'>+6.2%</font>) perks up on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16908088-biocept-executes-preferred-provider-agreement-scripps-health-plan-expanding-patient-coverage\" target=\"_blank\">preferred provider agreement</a> with Scripps Health Plan. Specific financial terms are not disclosed.</li><li>The company says the deal brings the total number of covered lives who have network access to its molecular diagnostic tests to more than 190M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286314\" data-linked=\"Biocept a preferred provider with Scripps Health, shares up 6%\" data-tweet=\"$BIOC - Biocept a preferred provider with Scripps Health, shares up 6% https://seekingalpha.com/news/3286314-biocept-preferred-provider-scripps-health-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3286314-biocept-preferred-provider-scripps-health-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286304\" data-ts=\"1502121682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286304-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/JOUT' title='Johnson Outdoors Inc.'>JOUT</a> <font color='green'>+6%.</font></li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ANDE' title='The Andersons, Inc.'>ANDE</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SUP' title='Superior Industries International Inc.'>SUP</a> <font color='red'>-6%</font>. AOI <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286304\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$FTFT $REV $JOUT - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3286304-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3286304-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286302\" data-ts=\"1502121471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CC\" target=\"_blank\">CC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286302-chemoursplus-1_5-ubs-upgrades-to-neutral-from-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chemours +1.5% as UBS upgrades to Neutral from Sell</a></h4><ul>     <li>Chemours (<a href='https://seekingalpha.com/symbol/CC' title='The Chemours Company'>CC</a> <font color='green'>+1.6%</font>) hits a new 52-week high before pulling back, as UBS <a href=\"https://www.streetinsider.com/Analyst+PT+Change/UBS+Upgrades+Chemours+%28CC%29+to+Neutral/13173646.html\" target=\"_blank\">upgrades</a> shares to  Neutral from Sell with a $50 price target, raised from $36, as the firm says the company  has exceeded expectations on cost cutting and fluoro-products growth.</li><li>CC's Q2 results included an H2 EBITDA guidance raise to $650M-$750M from $640M, prompting UBS to see a more balanced risk/reward for the stock going forward.</li><li>While UBS&nbsp;says its TiO2 outlook is essentially unchanged, its prior concerns  about CC's ability to deliver cost savings and fluoro-products growth have been disproved given the company's performance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286302\" data-linked=\"Chemours +1.5% as UBS upgrades to Neutral from Sell\" data-tweet=\"$CC - Chemours +1.5% as UBS upgrades to Neutral from Sell https://seekingalpha.com/news/3286302-chemoursplus-1_5-ubs-upgrades-to-neutral-from-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3286302-chemoursplus-1_5-ubs-upgrades-to-neutral-from-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286301\" data-ts=\"1502121416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ILMN\" target=\"_blank\">ILMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286301-canaccord-likes-illumina-sees-8-upside-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canaccord likes Illumina, sees 8% upside; shares ahead 2%</a></h4><ul><li>Canaccord Genuity upgrades Illumina (<a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a> <font color='green'>+2.2%</font>) to Buy with a $215 (8% upside) price target following its Q2 beat and revenue guidance raise based on bullish demand for NovaSeq.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3286301\" data-linked=\"Canaccord likes Illumina, sees 8% upside; shares ahead 2%\" data-tweet=\"$ILMN - Canaccord likes Illumina, sees 8% upside; shares ahead 2% https://seekingalpha.com/news/3286301-canaccord-likes-illumina-sees-8-upside-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3286301-canaccord-likes-illumina-sees-8-upside-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286296\" data-ts=\"1502120559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286296-first-data-down-2_5-after-earnings-bullish-intact-says-btig\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First Data down 2.5% after earnings; bullish these intact, says BTIG</a></h4><ul><li>Analyst Mark Palmer's <a href=\"http://researchwiseny.btig.com/ResearchLibraryAnalec/DownloadResearch.aspx?E=jbjbk-b\" target=\"_blank\">bull case has rested on</a> organic deleveraging driven by the company's robust free cash flow, modest revenue growth aided by the turnaround of the North American Global Business Solutions unit, and the conversion of significant operating advantage into much higher margins.</li><li>The Q2 results, he says, shows each of these items very much in evidence, and momentum for the stock -&nbsp;<font color='green'>up 30%</font>&nbsp;this year - should continue.</li><li>Investors are selling the news today, sending the stock&nbsp;<font color='red'>down 2.5</font><font color='red'>%</font>.</li><li>Palmer's $23 price target is&nbsp;<font color='green'>27% above</font>&nbsp;the current $18.11.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3286145-first-data-eps-line-beats-revenue\" target=\"_blank\">First Data EPS in-line, beats on revenue</a> (Aug. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286296\" data-linked=\"First Data down 2.5% after earnings; bullish these intact, says BTIG\" data-tweet=\"First Data down 2.5% after earnings; bullish these intact, says BTIG https://seekingalpha.com/news/3286296-first-data-down-2_5-after-earnings-bullish-intact-says-btig?source=tweet\" data-url=\"https://seekingalpha.com/news/3286296-first-data-down-2_5-after-earnings-bullish-intact-says-btig\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286295\" data-ts=\"1502120465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REV\" target=\"_blank\">REV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286295-beauty-sector-mounts-comeback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Beauty sector mounts a comeback</a></h4><ul> <li>Shares of Revlon (<a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a> <font color='green'>+6.3%</font>) and Avon Products (<a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a> <font color='green'>+1.4%</font>) take back some ground lost after both beauty companies posted subpar Q2 results last week. Coty (<a href='https://seekingalpha.com/symbol/COTY' title='Coty Inc.'>COTY</a> <font color='green'>+1%</font>) and Estee Lauder (<a href='https://seekingalpha.com/symbol/EL' title='Estee Lauder Companies, Inc. &#40;The&#41;'>EL</a> <font color='green'>+1.1%</font>) are also higher on the day.</li><li>Some analysts have suggested that the sector is oversold off of concerns on department store discounting.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3285890-revlon-reports-q2-results\" target=\"_blank\">Revlon reports Q2 results</a> (Aug. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285070-avon-products-misses-0_10-misses-revenue\" target=\"_blank\">Avon Products misses by $0.10, misses on revenue</a> (Aug. 3)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3286295\" data-linked=\"Beauty sector mounts a comeback\" data-tweet=\"$REV $REV $AVP - Beauty sector mounts a comeback https://seekingalpha.com/news/3286295-beauty-sector-mounts-comeback?source=tweet\" data-url=\"https://seekingalpha.com/news/3286295-beauty-sector-mounts-comeback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286294\" data-ts=\"1502120182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVE\" target=\"_blank\">CVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286294-reuters-cenovus-gets-pelican-lake-bids-from-canadian-natural-others\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Cenovus gets Pelican Lake bids from Canadian Natural, others</a></h4><ul>     <li>Cenovus Energy (<a href='https://seekingalpha.com/symbol/CVE' title='Cenovus Energy, Inc.'>CVE</a> <font color='red'>-3.2%</font>) has <a href=\"http://www.reuters.com/article/us-cenovus-energy-divestiture-idUSKBN1AK1X2\" target=\"_blank\">received bids</a> from Canadian Natural Resources (<a href='https://seekingalpha.com/symbol/CNQ' title='Canadian Natural Resources, Ltd.'>CNQ</a> <font color='green'>+0.8%</font>), ARC&nbsp;Financial and others for a heavy oil project in Pelican Lake, Alberta, that could be valued at as much as C$1B (US$796M), and is in advanced talks to sell another Alberta project which could fetch C$500M-C$600M, Reuters reports.</li>     <li>CVE also has received strong inbound interest from TransCanada (<a href='https://seekingalpha.com/symbol/TRP' title='TransCanada Corporation'>TRP</a>), Enbridge (<a href='https://seekingalpha.com/symbol/ENB' title='Enbridge Inc.'>ENB</a> <font color='red'>-0.1%</font>), Pembina Pipeline (<a href='https://seekingalpha.com/symbol/PBA' title='Pembina Pipeline Corp.'>PBA</a> <font color='red'>-1.2%</font>), Keyera (<a href='https://seekingalpha.com/symbol/KEYUF' title='Keyera Corp.'>OTC:KEYUF</a>) and Inter Pipeline (<a href='https://seekingalpha.com/symbol/IPPLF' title='Inter Pipeline Ltd'>OTCPK:IPPLF</a>) for buying all or parts of separate midstream assets in the Deep Basin, a region that straddles Alberta and British Columbia, although there is no formal sale process underway for the assets, according to the report.</li>     <li>CVE has been seeking buyers for parts of its portfolio to pay off debt used to partially fund its C$16.8B purchase of some ConocoPhillips assets in May.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286294\" data-linked=\"Reuters: Cenovus gets Pelican Lake bids from Canadian Natural, others\" data-tweet=\"$CVE $CVE $CNQ - Reuters: Cenovus gets Pelican Lake bids from Canadian Natural, others https://seekingalpha.com/news/3286294-reuters-cenovus-gets-pelican-lake-bids-from-canadian-natural-others?source=tweet\" data-url=\"https://seekingalpha.com/news/3286294-reuters-cenovus-gets-pelican-lake-bids-from-canadian-natural-others\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286291\" data-ts=\"1502119408\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NGVC\" target=\"_blank\">NGVC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286291-natural-grocers-vitamin-cottage-looks-to-recover\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural Grocers by Vitamin Cottage looks to recover</a></h4><ul> <li>Natural Grocers by Vitamin Cottage (<a href='https://seekingalpha.com/symbol/NGVC' title='Natural Grocers'>NGVC</a> <font color='green'>+5.9%</font>) trades higher after shaking off a bear call.</li> <li>Wolfe Research moves to a Market Perform stance on the specialty retailer from Underperform on a reset that follows the post-earnings plunge in NGVC.</li><li>Natural Grocers missed earnings and lowered full-year guidance, leading to a 30% drop in share price on Friday.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285606-natural-grocers-misses-0_09-misses-revenue\" target=\"_blank\">Natural Grocers misses by $0.09, misses on revenue</a> (Aug. 3)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3286291\" data-linked=\"Natural Grocers by Vitamin Cottage looks to recover\" data-tweet=\"$NGVC - Natural Grocers by Vitamin Cottage looks to recover https://seekingalpha.com/news/3286291-natural-grocers-vitamin-cottage-looks-to-recover?source=tweet\" data-url=\"https://seekingalpha.com/news/3286291-natural-grocers-vitamin-cottage-looks-to-recover\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286289\" data-ts=\"1502119320\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286289-grubhubplus-4_5-morgan-stanley-boosts-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GrubHub +4.5% as Morgan Stanley boosts to Buy</a></h4><ul>   <li>GrubHub (NYSE:<a href='https://seekingalpha.com/symbol/GRUB' title='GrubHub Inc.'>GRUB</a>) is on the move again today, <font color='green'>up 4.5%</font> after an upgrade and generous price target from Morgan Stanley.</li>    <li>That's a <font color='green'>14.2% move up</font> since the company got into a <a href=\"https://seekingalpha.com/news/3285495-grubhub-paying-287_5m-eat24-partnering-yelp\" target=\"_blank\">deal to buy Yelp's Eat24</a> and partner with the business-review site on food delivery.</li>    <li>The Eat24 deal followed two other GrubHub purchase deals, for Foodler and OrderUp, and the larger revenue base gives the company earnings power, says MS analyst Brian Nowak in an upgrade to Overweight.</li>    <li>The high-margin moves could add $80M to 2018 EBITDA, an increase of more than a third, he writes.</li>    <li>Nowak boosted GrubHub's price target to $59 from $43, implying 7.3% upside from today's higher price. He says growing scale could even prompt a higher multiple than the one he's applying (about 17 times EV/EBITDA) to give it a path to around $66/share (20% upside).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286289\" data-linked=\"GrubHub +4.5% as Morgan Stanley boosts to Buy\" data-tweet=\"$GRUB - GrubHub +4.5% as Morgan Stanley boosts to Buy https://seekingalpha.com/news/3286289-grubhubplus-4_5-morgan-stanley-boosts-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3286289-grubhubplus-4_5-morgan-stanley-boosts-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286288\" data-ts=\"1502119121\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RMAX\" target=\"_blank\">RMAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286288-stephens-rings-register-on-re-max-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stephens rings the register on Re/Max; shares down 4%</a></h4><ul><li>Valuation seems full after the stock's&nbsp;<font color='green'>43% gain</font>&nbsp;over the past year, says analyst John Campbell, and there isn't a whole lot of clarity concerning near-term catalysts.</li><li>He downgrades to Equalweight from Overweight and cuts the price target to $64 from $66.</li><li><a href='https://seekingalpha.com/symbol/RMAX' title='RE/MAX Holdings, Inc.'>RMAX</a>&nbsp;<font color='red'>-3.95%</font>&nbsp;to $62.05.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285469-re-max-holdings-beats-0_06-beats-revenue\" target=\"_blank\">RE/MAX Holdings beats by $0.06, beats on revenue</a> (Aug. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286288\" data-linked=\"Stephens rings the register on Re/Max; shares down 4%\" data-tweet=\"$RMAX - Stephens rings the register on Re/Max; shares down 4% https://seekingalpha.com/news/3286288-stephens-rings-register-on-re-max-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3286288-stephens-rings-register-on-re-max-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286285\" data-ts=\"1502118553\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286285-fda-tentatively-oks-mylans-generic-combo-tld-for-u-s-aids-relief-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA tentatively OKs Mylan&#39;s generic combo TLD for U.S. AIDS relief program</a></h4><ul><li>Mylan N.V. (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='red'>-2.3%</font>) <a href=\"https://seekingalpha.com/pr/16908032-mylan-receives-tentative-approval-tld-pepfar\" target=\"_blank\">announces </a>that its generic fixed-dose combo HIV med TLD has been tentatively approved by the FDA under the U.S. President's Emergency Plan for AIDS Relief. The drug will be available in developing countries for the first-line treatment of HIV/AIDS.</li><li>TLD combines generic versions of ViiV Healthcare's Tivicay (dolutegravir) and Epivir (lamivudine) and Gilead Sciences' Viread (tenofovir disoproxil fumarate).</li></ul><div class=\"tiny-share-widget\" data-id=\"3286285\" data-linked=\"FDA tentatively OKs Mylan&#39;s generic combo TLD for U.S. AIDS relief program\" data-tweet=\"$MYL - FDA tentatively OKs Mylan&#39;s generic combo TLD for U.S. AIDS relief program https://seekingalpha.com/news/3286285-fda-tentatively-oks-mylans-generic-combo-tld-for-u-s-aids-relief-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3286285-fda-tentatively-oks-mylans-generic-combo-tld-for-u-s-aids-relief-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286260\" data-ts=\"1502118218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286260-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a> <font color='green'>+80%</font>. <a href='https://seekingalpha.com/symbol/NXTM' title='NxStage Medical, Inc.'>NXTM</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California'>PACB</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='red'>-56%</font>. <a href='https://seekingalpha.com/symbol/GEMP' title='Gemphire Therapeutics'>GEMP</a> <font color='red'>-52%</font>. <a href='https://seekingalpha.com/symbol/FLDM' title='Fluidigm Corporation'>FLDM</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286260\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$MYOK $NXTM $EDIT - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3286260-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3286260-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286282\" data-ts=\"1502117788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286282-china-iron-ore-gains-lift-rio-tinto-bhp-to-52-week-highs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China iron ore gains lift Rio Tinto, BHP to 52-week highs</a></h4><ul>     <li><a href=\"https://www.wsj.com/articles/global-markets-start-the-week-higher-1502072634\" target=\"_blank\">Global miners surge</a> in early trading, with Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='green'>+2.3%</font>) and BHP&nbsp;Billiton (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='green'>+1.4%</font>) reaching new 52-week highs, as China iron ore prices jumped as much as 7% overnight.</li>     <li>Vale (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='green'>+2.6%</font>), Glencore (<a href='https://seekingalpha.com/symbol/GLCNF' title='Glencore Plc'>OTCPK:GLCNF</a>, <a href='https://seekingalpha.com/symbol/GLNCY' title='Glencore Plc ADR'>OTCPK:GLNCY</a>), Anglo American (<a href='https://seekingalpha.com/symbol/AAUKF' title='Anglo American plc'>OTCQX:AAUKF</a>, <a href='https://seekingalpha.com/symbol/AAUKY' title='Anglo American plc ADR'>OTCPK:AAUKY</a>) and Fortescue Metals (<a href='https://seekingalpha.com/symbol/FSUMF' title='Fortescue Metals Group Ltd'>OTCQX:FSUMF</a> <font color='green'>+1.1%</font>) also are higher after Dalian iron ore futures rose to a four-month high while Shanghai steel rebar reached its best levels in five years.</li>     <li>&ldquo;There&rsquo;s a bit of a relief effect coming from China,&rdquo; says Didier Saint-Georges, member of the Investment Committee at Carmignac. &ldquo;[Economic] momentum in China has been quite good, and these fears about demand for commodities and the mining sector were probably not well placed.\"</li>     <li>Also: <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color='green'>+4.6%</font>, <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='green'>+3.1%</font>, <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='green'>+1.4%</font>, <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='green'>+2.9%</font>, <a href='https://seekingalpha.com/symbol/CMC' title='Commercial Metals Company'>CMC</a> <font color='green'>+1.1%</font>, <a href='https://seekingalpha.com/symbol/RS' title='Reliance Steel & Aluminum Co.'>RS</a> <font color='green'>+1.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286282\" data-linked=\"China iron ore gains lift Rio Tinto, BHP to 52-week highs\" data-tweet=\"$RIO $RIO $BHP - China iron ore gains lift Rio Tinto, BHP to 52-week highs https://seekingalpha.com/news/3286282-china-iron-ore-gains-lift-rio-tinto-bhp-to-52-week-highs?source=tweet\" data-url=\"https://seekingalpha.com/news/3286282-china-iron-ore-gains-lift-rio-tinto-bhp-to-52-week-highs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286278\" data-ts=\"1502117493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CANF\" target=\"_blank\">CANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286278-can-fite-wraps-up-cardiodynamic-study-on-lead-product-candidate-piclidenoson-phase-3-studies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Can-Fite wraps up cardiodynamic study on lead product candidate piclidenoson, Phase 3 studies on deck; shares slip 6%</a></h4><ul><li>Can-Fite BioPharma (<a href='https://seekingalpha.com/symbol/CANF' title='Can-Fite BioPharma Ltd.'>CANF</a> <font color='red'>-5.8%</font>) <a href=\"https://seekingalpha.com/pr/16907865-can-fite-successfully-completes-human-cardiodynamic-safety-trial-piclidenoson\" target=\"_blank\">successfully completes</a> a cardiodynamic trial on lead candidate piclidenoson (CF101), an FDA- and EMA-specified safety requirement before starting Phase 3 studies in rheumatoid arthritis and psoriasis.</li><li>The cardiodynamic trial was a placebo-controlled crossover study assessing the effect of piclidenoson on electrocardiograms of healthy volunteers. No safety signals were observed.</li><li><a href=\"http://www.canfite.com/?KPageId=19\" target=\"_blank\">Piclidenoson&nbsp;</a>is an anti-inflammatory oral small molecule drug. Its mechanism of action is mediating&nbsp;<a href=\"http://en.wikipedia.org/wiki/Adenosine_A3_receptor\" target=\"_blank\">A3 adenosine receptors</a>, key signalling proteins which play key roles in the production of inflammatory cytokines.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3219177-design-late-stage-study-can-fites-lead-product-candidate-okd-europe-trial-start-h2-2017\" target=\"_blank\">Design of late-stage study of Can-Fite's lead product candidate OK'd in Europe, trial to start in H2 2017</a> (Nov. 1, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286278\" data-linked=\"Can-Fite wraps up cardiodynamic study on lead product candidate piclidenoson, Phase 3 studies on deck; shares slip 6%\" data-tweet=\"$CANF - Can-Fite wraps up cardiodynamic study on lead product candidate piclidenoson, Phase 3 studies on deck; shares slip 6% https://seekingalpha.com/news/3286278-can-fite-wraps-up-cardiodynamic-study-on-lead-product-candidate-piclidenoson-phase-3-studies?source=tweet\" data-url=\"https://seekingalpha.com/news/3286278-can-fite-wraps-up-cardiodynamic-study-on-lead-product-candidate-piclidenoson-phase-3-studies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286277\" data-ts=\"1502116527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDIT\" target=\"_blank\">EDIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286277-editas-medicine-up-14-ahead-of-q2-results-on-wednesday\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Editas Medicine up 14% ahead of Q2 results on Wednesday</a></h4><ul><li>Gene editing firm Editas Medicine (<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='green'>+14.3%</font>) shows some life ahead its <a href=\"https://seekingalpha.com/pr/16908053-editas-medicine-host-conference-call-discussing-second-quarter-2017-corporate-update-results\" target=\"_blank\">Q2 report </a>on Wednesday afternoon after the close. Consensus view is a loss of ($0.71) per share on revenue of $2.4M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286277\" data-linked=\"Editas Medicine up 14% ahead of Q2 results on Wednesday\" data-tweet=\"$EDIT - Editas Medicine up 14% ahead of Q2 results on Wednesday https://seekingalpha.com/news/3286277-editas-medicine-up-14-ahead-of-q2-results-on-wednesday?source=tweet\" data-url=\"https://seekingalpha.com/news/3286277-editas-medicine-up-14-ahead-of-q2-results-on-wednesday\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286275\" data-ts=\"1502116102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FISV\" target=\"_blank\">FISV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286275-fiserv-raises-monitise-bid-to-75m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fiserv raises Monitise bid to £75M</a></h4><ul>     <li>Fiserv (<a href=\"http://seekingalpha.com/symbol/FISV\" target=\"_blank\">FISV</a> <font color='green'>+0.4%</font>) has <a href=\"https://www.reuters.com/article/us-hearst-iflix-investment-idUSKBN1AN1I7?feedType=nl&amp;feedName=innovationNews&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=US%20Deals%20Today%202017-08-07&amp;utm_term=US%20Deals%20Today\" target=\"_blank\">boosted its offer for Monitise</a> (<a href=\"http://seekingalpha.com/symbol/MONIF\" target=\"_blank\">MONIF</a> <font color='green'>+2.2%</font>) to about &pound;75M (around $98M), a raise from a previous offer around &pound;70M.</li>     <li>That's still a precipitous fall from Monitise's value of more than &pound;1B three years ago.</li>     <li>The new final offer is a premium of 34.8% over Monitise's London closing price the session before the initial offer was made in June.</li>     <li>Monitise's board is unanimous in recommending the new bid of 3.1 pence/share in cash.</li>     <li>Fiserv had letters of intent or irrevocable undertakings for 229.6M shares, some 9.9% of Monitise's existing issued share capital.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286275\" data-linked=\"Fiserv raises Monitise bid to £75M\" data-tweet=\"$FISV $FISV $MONIF - Fiserv raises Monitise bid to £75M https://seekingalpha.com/news/3286275-fiserv-raises-monitise-bid-to-75m?source=tweet\" data-url=\"https://seekingalpha.com/news/3286275-fiserv-raises-monitise-bid-to-75m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286274\" data-ts=\"1502116093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKD\" target=\"_blank\">BKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286274-stall-in-sale-sends-brookfield-senior-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stall in sale sends Brookfield Senior down 7%</a></h4><ul><li><a href=\"https://www.ft.com/content/96da3aa0-7b54-11e7-9108-edda0bcbc928\" target=\"_blank\">According to the <em>FT</em></a>, possible suitor&nbsp;Zhonghong Zhuoye Group is having trouble lining up financing thanks to tightened Chinese regulations on overseas investments.</li><li>Brookdale Senior Living (<a href='https://seekingalpha.com/symbol/BKD' title='Brookdale Senior Living Inc.'>BKD</a> <font color='red'>-7.1%</font>) earlier this summer was reported to be near a sale to&nbsp;Zhonghong Zhuoye. The rumored price in the area of $4B would make it one of the largest Chinese offshore deals of the year.</li><li>The FT's source says that while Beijing has not rejected funding,&nbsp;Zhonghong is now considered \"high risk.\"</li><li>Zhonghong earlier this year purchased a 21% stake in SeaWorld Entertainment from Blackstone for $429M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286274\" data-linked=\"Stall in sale sends Brookfield Senior down 7%\" data-tweet=\"$BKD - Stall in sale sends Brookfield Senior down 7% https://seekingalpha.com/news/3286274-stall-in-sale-sends-brookfield-senior-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3286274-stall-in-sale-sends-brookfield-senior-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286268\" data-ts=\"1502114879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286268-price-target-changes-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Price target changes - healthcare</a></h4><ul><li>Mylan N.V. (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='red'>-1.5%</font>) PT lowered to $36 (3% upside) from $52 by Morgan Stanley ahead of Q2 earnings on Wednesday.</li><li>Juno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a>) PT raised to $27 (12% downside risk) from $26 by Morgan Stanley.</li><li>Natera (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRA' title='Natera'>NTRA</a>) PT lowered to $13 (39% downside risk)&nbsp;from $18 by Morgan Stanley. Overweight rating maintained.</li><li>bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) PT raised to $105 (8% upside)&nbsp;from $103 by Morgan Stanley.</li><li>Select Medical Holdings (NYSE:<a href='https://seekingalpha.com/symbol/SEM' title='Select Medical Holdings Corporation'>SEM</a>) PT raised to $20 (12% upside)&nbsp;by Benchmark.</li><li>MyoKardia (NASDAQ:<a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a>) PT raised to $48 (53% upside)&nbsp;by Wells Fargo after positive mid-stage results on mavacamten.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286268\" data-linked=\"Price target changes - healthcare\" data-tweet=\"$MYL $MYL $JUNO - Price target changes - healthcare https://seekingalpha.com/news/3286268-price-target-changes-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3286268-price-target-changes-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286267\" data-ts=\"1502114835\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOV\" target=\"_blank\">NOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286267-national-oilwell-varco-cut-to-sell-suntrust\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Oilwell Varco cut to Sell at SunTrust</a></h4><ul>     <li>National Oilwell Varco (<a href='https://seekingalpha.com/symbol/NOV' title='National Oilwell Varco, Inc.'>NOV</a> <font color='red'>-2.8%</font>) is <a href=\"http://www.marketwatch.com/story/national-oilwell-varcos-stock-falls-after-analyst-downgrades-rating-slashed-price-target-2017-08-07\" target=\"_blank\">downgraded to Sell</a> from Hold with a $29 price target, cut from $40, at SunTrust, based on valuation and the firm's belief that oil prices will drift below $50/bbl in November and December.</li><li>SunTrust says that while NOV is a \"great company\" with \"great management\" and a \"great balance sheet,\" it believes past returns from the company's rig systems business will will not repeat in the next five or more years.</li><li>\"Expectations implied by NOV's share price appear overly optimistic, in our opinion, based on our 12-18 month outlook,\" SunTrust's Ken Sill writes. \"NOV's share price implies 2018 estimates will rise [but] we think they need to fall.\"</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3286267\" data-linked=\"National Oilwell Varco cut to Sell at SunTrust\" data-tweet=\"$NOV - National Oilwell Varco cut to Sell at SunTrust https://seekingalpha.com/news/3286267-national-oilwell-varco-cut-to-sell-suntrust?source=tweet\" data-url=\"https://seekingalpha.com/news/3286267-national-oilwell-varco-cut-to-sell-suntrust\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286265\" data-ts=\"1502114467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONDK\" target=\"_blank\">ONDK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286265-ondeck-capital-up-6-after-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OnDeck Capital up more than 6% after earnings beat</a></h4><ul><li>Q2 originations of $464.4M fell 19% from Q1 following the company's decision to tighten underwriting. The provision rate fell to 7.2% from 8.7%. UPB of $953.8M fell 7% Q/Q, an rose 21% Y/Y.</li><li>Adjusted EBITDA of $3.3M vs. a negative $12.4M a year earlier.</li><li>Full-year guidance is reiterated: Revenue of $342M-$352M, and adjusted EBITDA of $5M-$15M. Q3 revenue is seen at $82M-$86M, with adjusted EBITDA of $1M-$5M.</li><li>Partnership with JPMorgan has been expanded to up to four years.</li><li>Further progress made on $45M cost-saving plan lowered annual operating expense rate to $160M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3286143-ondeck-capital-beats-0_03-misses-revenue\" target=\"_blank\">OnDeck Capital beats by $0.03, misses on revenue</a> (Aug. 7)</li><li><a href='https://seekingalpha.com/symbol/ONDK' title='OnDeck Capital'>ONDK</a>&nbsp;<font color='green'>+6.15%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3286265\" data-linked=\"OnDeck Capital up more than 6% after earnings beat\" data-tweet=\"$ONDK - OnDeck Capital up more than 6% after earnings beat https://seekingalpha.com/news/3286265-ondeck-capital-up-6-after-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3286265-ondeck-capital-up-6-after-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286263\" data-ts=\"1502114225\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286263-mylans-epipen-still-commands-25-of-u-s-market-thanks-to-pbm-contracts-wsj\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mylan&#39;s EpiPen still commands 25% of U.S. market thanks to PBM contracts - WSJ</a></h4><ul><li>The Wall Street Journal <a href=\"https://www.wsj.com/articles/behind-the-push-to-keep-higher-priced-epipen-in-consumers-hands-1502036741\" target=\"_blank\">reports </a>that Mylan (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='red'>-2.3%</font>) remains in a leading position in the U.S. market for emergency allergy medications despite the higher cost of its EpiPen (epinephrine injection), commanding a market share of more than 25%.</li><li>The company has been able to hold onto a healthy share of the business despite non-branded/competitive alternatives through its contracts with pharmacy benefit managers like Express Scripts and CVS Health, who prioritize EpiPen because the margins are better.</li><li>Express Scripts counters that it does block use of the brand-name EpiPen in many health plans, but it covers both the brand and the generic in other plans to ensure there is enough supply.</li><li>CVS adds that almost 60% of its customers are using the generic alternative to EpiPen.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3273808-fda-oks-adamis-pharmas-epinephrine-auto-injector-shares-34-percent-mylan-3-percent\" target=\"_blank\">FDA OKs Adamis Pharma's epinephrine auto-injector; shares up 34%; Mylan down 3%</a> (June 15)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3270799-taxpayers-overpaid-1_3b-epipen-800m-mylan-claimed-shares-ease-1-percent\" target=\"_blank\">Taxpayers overpaid $1.3B for EpiPen, $800M more than Mylan claimed; shares ease 1%</a> (May 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286263\" data-linked=\"Mylan&#39;s EpiPen still commands 25% of U.S. market thanks to PBM contracts - WSJ\" data-tweet=\"$MYL - Mylan&#39;s EpiPen still commands 25% of U.S. market thanks to PBM contracts - WSJ https://seekingalpha.com/news/3286263-mylans-epipen-still-commands-25-of-u-s-market-thanks-to-pbm-contracts-wsj?source=tweet\" data-url=\"https://seekingalpha.com/news/3286263-mylans-epipen-still-commands-25-of-u-s-market-thanks-to-pbm-contracts-wsj\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286256\" data-ts=\"1502113037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/S\" target=\"_blank\">S</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286256-sprint-reportedly-talking-merger-t-mobile-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint reportedly talking merger with T-Mobile again</a></h4><ul>   <li>Not especially surprisingly, Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>) is <a href=\"https://www.bloomberg.com/news/articles/2017-08-07/sprint-is-said-to-resume-preliminary-talks-on-t-mobile-merger\" target=\"_blank\">back in talks about merging with T-Mobile</a> (NASDAQ:<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a>) after last week's tie-up talks for the carrier were dominated by Charter's (<a href=\"http://seekingalpha.com/symbol/CHTR\" target=\"_blank\">CHTR</a> <font color='red'>-0.3%</font>) <a href=\"https://seekingalpha.com/news/3283169-wsj-charter-sprint-deal\" target=\"_blank\">rebuffing talk of a merger</a>.</li>    <li>Sprint is <font color='green'>1.8% higher</font> out of the open today; <a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a> <font color='green'>up 0.4%</font>.</li>    <li>The two started talking again once an exclusive window for Sprint to talk with Charter and Comcast (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='green'>+0.1%</font>) expired, Bloomberg reports. Along with Sprint CEO Marcelo Claure's saying a decision of some kind is close, it's an indication that Sprint Chairman Masayoshi Son is determined to deal as part of Sprint's salvation.</li>    <li>Today in Tokyo, Son added that a decision on Sprint's future is close at SoftBank (<a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a>), the majority owner of Sprint that's considering a buyout offer for Charter.</li>    <li>SoftBank shares <font color='green'>rose 2.4%</font> in Tokyo today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286256\" data-linked=\"Sprint reportedly talking merger with T-Mobile again\" data-tweet=\"$S $S $TMUS - Sprint reportedly talking merger with T-Mobile again https://seekingalpha.com/news/3286256-sprint-reportedly-talking-merger-t-mobile-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3286256-sprint-reportedly-talking-merger-t-mobile-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>262&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286252\" data-ts=\"1502112528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSTG\" target=\"_blank\">BSTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286252-biostage-announces-first-u-s-esophageal-implant-shares-ahead-33-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biostage announces first U.S. esophageal implant; shares ahead 33% premarket</a></h4><ul><li>The first U.S. patient has been <a href=\"https://seekingalpha.com/pr/16907882-biostage-announces-use-esophageal-implant-product-candidate-patient\" target=\"_blank\">implanted </a>with BioStage's (<a href='https://seekingalpha.com/symbol/BSTG' title='Biostage, Inc.'>OTC:BSTG</a>) <a href=\"http://www.biostage.com/cellspan-esophageal-implants\" target=\"_blank\">Cellspan Esophageal Implant</a>. The surgery took place in early May in a male patient with a tumor in his chest that was encroaching on his lung, heart and esophagus. The patient is alive and the company says Cellspan has performed as expected.</li><li>The Cellspan Esophageal Implant is a regenerative medicine product that uses the patient's own cells to seed and grow on a <a href=\"http://www.biostage.com/regeneration-across-multiple-indications\" target=\"_blank\">biocompatible scaffold</a>.</li><li>Shares are up&nbsp;<font color='green'>33%</font>&nbsp;premarket on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286252\" data-linked=\"Biostage announces first U.S. esophageal implant; shares ahead 33% premarket\" data-tweet=\"$BSTG - Biostage announces first U.S. esophageal implant; shares ahead 33% premarket https://seekingalpha.com/news/3286252-biostage-announces-first-u-s-esophageal-implant-shares-ahead-33-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3286252-biostage-announces-first-u-s-esophageal-implant-shares-ahead-33-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286251\" data-ts=\"1502112447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286251-blackberryminus-3_4-goldman-resumes-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry -3.4% as Goldman resumes at Sell</a></h4><ul>   <li>BlackBerry (BBRY) shares are <font color='red'>3.4% lower</font> in premarket trading after Goldman Sachs has resumed coverage with a Sell rating.</li>    <li>Rivals such as Citrix, VMware and Microsoft look to be bundling enterprise mobility management more broadly (and from a bigger footprint), turning up competitive pressures, writes analyst Gabriela Borges.</li>    <li>There's also limited visibility on the company's opportunity in the automotive market, she writes. There's risk in Street expectations for estimates in the second half and fiscal 2019.</li>    <li>Goldman's price target of $8.50 implies 10% downside from the current price of $9.44.</li>    <li>BBRY is <font color='green'>up 37%</font> in 2017.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286251\" data-linked=\"BlackBerry -3.4% as Goldman resumes at Sell\" data-tweet=\"$BB - BlackBerry -3.4% as Goldman resumes at Sell https://seekingalpha.com/news/3286251-blackberryminus-3_4-goldman-resumes-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3286251-blackberryminus-3_4-goldman-resumes-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>76&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286249\" data-ts=\"1502112333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286249-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a> <font color='green'>+34%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3286161-myokardia-misses-0_06-misses-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/NXTM' title='NxStage Medical, Inc.'>NXTM</a> <font color='green'>+28%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3286102-nxstage-medical-misses-0_01-misses-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a> <font color='green'>+21%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3286247-eros-international-plus-22-percent-word-possible-1b-apple-deal\" target=\"_blank\">selling</a> its entire content library to Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>).</li>     <li>CLNT <font color='green'>+18%</font>&nbsp;on&nbsp;signing&nbsp;an <a href=\"https://seekingalpha.com/news/3286197-cleantech-enters-agreement-ecoin-global\" target=\"_blank\">agreement</a> with ECoin Global Limited</li>     <li><a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a> <font color='green'>+14%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3286162-key-regulators-board-athersys-clinical-development-plan-multistem-shares-ahead-2-percent\" target=\"_blank\">announcement</a>&nbsp;that the European Medicines Agency &#40;EMA&#41;&nbsp;has agreed that the design of its Phase 3 clinical trial.</li>     <li><a href='https://seekingalpha.com/symbol/HZNP' title='Horizon Pharma plc'>HZNP</a> <font color='green'>+13%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3286146-horizon-pharma-beats-0_31-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a> <font color='green'>+10%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16908204-fda-grants-orphan-drug-designation-kadmon-s-tesevatinib-treatment-egfr-mutated-non-small-cell\" target=\"_blank\">granting</a> orphan drug designation to tesevatinib, the Company&rsquo;s oral tyrosine kinase inhibitor, for the treatment of non-small cell lung cancer (NSCLC) with epithelial growth factor receptor (EGFR)-activating mutations.</li>     <li>[BIOC]] <font color='green'>+8%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/COL' title='Rockwell Collins, Inc.'>COL</a> <font color='green'>+8%</font>&nbsp;on potential UTX-COL <a href=\"https://seekingalpha.com/news/3286232-jpmorgan-comments-potential-utx-col-deal\" target=\"_blank\">deal</a></li>     <li><a href='https://seekingalpha.com/symbol/CRNT' title='Ceragon Networks Ltd.'>CRNT</a> <font color='green'>+6%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3286144-ceragon-networks-beats-0_01-beats-revenue\" target=\"_blank\">result</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286249\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$MYOK $NXTM $EROS - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3286249-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3286249-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286248\" data-ts=\"1502111980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286248-mylan-down-4-premarket-in-sympathy-teva-q2-earnings-august-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mylan down 4% premarket in sympathy with Teva; Q2 earnings August 9</a></h4><ul><li>Mylan N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>) is joined at the hip with Teva. Shares are down&nbsp;<font color='red'>4%</font>&nbsp;premarket on robust volume, matching Teva's decline. Q2 earnings are on tap for Wednesday, August 9 before the open.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285953-tevas-travails-bearish-mylan-rbc\" target=\"_blank\">Teva's travails bearish for Mylan - RBC</a> (Aug. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286248\" data-linked=\"Mylan down 4% premarket in sympathy with Teva; Q2 earnings August 9\" data-tweet=\"$MYL - Mylan down 4% premarket in sympathy with Teva; Q2 earnings August 9 https://seekingalpha.com/news/3286248-mylan-down-4-premarket-in-sympathy-teva-q2-earnings-august-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3286248-mylan-down-4-premarket-in-sympathy-teva-q2-earnings-august-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286247\" data-ts=\"1502111855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROS\" target=\"_blank\">EROS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286247-eros-internationalplus-22-after-word-of-possible-1b-apple-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eros International +22% after word of possible $1B Apple deal</a></h4><ul>   <li>Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) shares are <font color='green'>up 22%</font> premarket in response to the news that it could strike a <a href=\"https://seekingalpha.com/news/3286226-apple-might-purchase-content-library-indian-media-company\" target=\"_blank\">$1B-plus content deal</a> with Apple.</li>    <li>The deal would not only give Apple a foothold against Netflix in a push into India, but relieve what have been lingering cash crunch concerns as Eros struggles with film financing.</li>    <li>Shares of the company are <font color='red'>down 37.2%</font> YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286247\" data-linked=\"Eros International +22% after word of possible $1B Apple deal\" data-tweet=\"$EROS - Eros International +22% after word of possible $1B Apple deal https://seekingalpha.com/news/3286247-eros-internationalplus-22-after-word-of-possible-1b-apple-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3286247-eros-internationalplus-22-after-word-of-possible-1b-apple-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286242\" data-ts=\"1502111598\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286242-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a>&nbsp;<font color='red'>-57%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3286181-zynerbas-zyn002-flunks-mid-stage-epilepsy-study-shares-48-percent-premarket\" target=\"_blank\">announcing</a> top-line results from Phase 2 STAR 1 trial of ZYN002 in adult epilepsy patients.</li><li><a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a> <font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16907983-metlife-completes-spin-brighthouse-financial\" target=\"_blank\">completing</a> spin-off of Brighthouse Financial.</li><li><a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a>&nbsp;<font color='red'>-7%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3286207-intrepid-potash-cut-sell-ubs-last-weeks-big-gains\" target=\"_blank\">downgraded</a> by UBS.</li><li><a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16908068-data-monitoring-committee-completes-mid-study-review-celsion-s-phase-iii-thermodox-optima\" target=\"_blank\">completing</a> mid-study review of Phase III ThermoDox Optima Study in liver cancer.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3286242\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$ZYNE $MET $IPI - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3286242-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3286242-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286241\" data-ts=\"1502111491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOK\" target=\"_blank\">MYOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286241-myokardia-up-35-premarket-on-positive-mavacamten-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MyoKardia up 35% premarket on positive mavacamten results</a></h4><ul><li>Thinly traded MyoKardia (NASDAQ:<a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a>) is up&nbsp;<font color='green'>35%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16907899-myokardia-reports-positive-topline-results-phase-2-pioneer-hcm-study-mavacamten-formerly\" target=\"_blank\">announcement </a>of positive results from the first cohort in a Phase 2 clinical trial, PIONEER-HCM, assessing mavacamten (MYK-461) in patients with symptomatic obstructive hypertrophic cardiomyopathy.</li><li>All the patients in the cohort (n=10) experienced a statistically valid reduction in post-exercise peak left ventricular outflow tract &#40;LVOT&#41; gradient from baseline to week 12.</li><li>The Independent Data Monitoring Committee has recommended the continuation of the study.</li><li>The company intends to advance mavacamten into a pivotal study, EXPLORER-HCM, by year-end.</li><li>Mavacamten is an orally available small molecule designed to reduce left ventricular contractility by modulating the function of cardiac myosin, the protein that drives heart muscle contraction.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286241\" data-linked=\"MyoKardia up 35% premarket on positive mavacamten results\" data-tweet=\"$MYOK - MyoKardia up 35% premarket on positive mavacamten results https://seekingalpha.com/news/3286241-myokardia-up-35-premarket-on-positive-mavacamten-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3286241-myokardia-up-35-premarket-on-positive-mavacamten-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286231\" data-ts=\"1502110418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPHRY\" target=\"_blank\">SPHRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286231-starpharmas-vivagel-bv-successful-in-two-late-stage-studies-in-bacterial-vaginosis-u-s\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Starpharma&#39;s VivaGel BV successful in two late-stage studies in bacterial vaginosis; U.S. marketing application planned</a></h4><ul><li>Melbourne, Australia-based Starpharma (<a href='https://seekingalpha.com/symbol/SPHRY' title='Starpharma Holdings Ltd. ADR'>OTCQX:SPHRY</a>) <a href=\"https://seekingalpha.com/pr/16908022-starpharma-successful-vivagel-phase-3-results-nda-planned-rbv\" target=\"_blank\">announces </a>successful results from two Phase 3 clinical trials assessing VivaGel BV for the prevention of recurrent bacterial vaginosis &#40;BV&#41;. Both studies achieved their primary endpoints.</li><li>In the U.S. study, the rate of BV recurrence at or by week 16 was 44.2% in the VivaGel cohort compared to 54.3% for placebo (p=0.015). In the European study, the rates were 15.7% and 22.6%, respectively (p=0.027).</li><li>The company intends to submit its marketing to the FDA as soon as feasible considering it has QIDP and Fast Track status.</li><li>It is currently negotiating with unnamed parties for regional/global commercial rights to the product.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286231\" data-linked=\"Starpharma&#39;s VivaGel BV successful in two late-stage studies in bacterial vaginosis; U.S. marketing application planned\" data-tweet=\"$SPHRY - Starpharma&#39;s VivaGel BV successful in two late-stage studies in bacterial vaginosis; U.S. marketing application planned https://seekingalpha.com/news/3286231-starpharmas-vivagel-bv-successful-in-two-late-stage-studies-in-bacterial-vaginosis-u-s?source=tweet\" data-url=\"https://seekingalpha.com/news/3286231-starpharmas-vivagel-bv-successful-in-two-late-stage-studies-in-bacterial-vaginosis-u-s\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286225\" data-ts=\"1502109686\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GM\" target=\"_blank\">GM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286225-gm-recalls-690k-chevy-gmc-pickups\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GM recalls 690K Chevy/GMC pickups</a></h4><ul> <li>General Motors (NYSE:<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a>) issues a recall on over 690K 2014 Chevy Silverado and 2014 GMC Sierra pickups due to a potential software issue that could impact steerinng.</li> <li>Defect description: \"These vehicles may experience a temporary loss of electric power steering (NYSEARCA:<a href='https://seekingalpha.com/symbol/EPS' title='WisdomTree Earnings 500 ETF'>EPS</a>) assist followed by a sudden return of EPS assist, particularly during low-speed turning maneuvers.\"</li> <li><a href=\"https://static.nhtsa.gov/odi/rcl/2017/RCLRPT-17V414-2815.PDF\" target=\"_blank\">NHTSA safety recall report</a> (.pdf)</li> <li>Shares of GM are <font color='red'>down 0.31%</font> to $35.16 in premarket action.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286225\" data-linked=\"GM recalls 690K Chevy/GMC pickups\" data-tweet=\"$GM $GM $EPS - GM recalls 690K Chevy/GMC pickups https://seekingalpha.com/news/3286225-gm-recalls-690k-chevy-gmc-pickups?source=tweet\" data-url=\"https://seekingalpha.com/news/3286225-gm-recalls-690k-chevy-gmc-pickups\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286224\" data-ts=\"1502109624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMI\" target=\"_blank\">CMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286224-moves-on-goldmans-conviction-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moves on Goldman&#39;s Conviction Buy</a></h4><ul><li>Cummins (NYSE:<a href='https://seekingalpha.com/symbol/CMI' title='Cummins Inc.'>CMI</a>) has been downgraded to Buy from Conviction Buy at Goldman Sachs, while Deere (NYSE:<a href='https://seekingalpha.com/symbol/DE' title='Deere & Company'>DE</a>) has been added to the coveted list.</li><li>On Deere: \"We believe farm machinery demand is at an inflection, entering the first quarter of a multi-year recovery despite trough farmer profitability.\"</li><li>CMI has <font color='red'>fallen about 3%</font>  over the past month, while DE has <font color='green'>climbed almost 4%.</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3286224\" data-linked=\"Moves on Goldman&#39;s Conviction Buy\" data-tweet=\"$CMI $CMI $DE - Moves on Goldman&#39;s Conviction Buy https://seekingalpha.com/news/3286224-moves-on-goldmans-conviction-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3286224-moves-on-goldmans-conviction-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286222\" data-ts=\"1502109441\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEMP\" target=\"_blank\">GEMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286222-gemphires-cholesterol-med-gemcabene-successful-in-mid-stage-study-treatment-effect-less\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gemphire&#39;s cholesterol med gemcabene successful in mid-stage study but treatment effect less than previous trial; shares down 36% premarket</a></h4><ul><li>Thinly traded Gemphire Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GEMP' title='Gemphire Therapeutics'>GEMP</a>) craters&nbsp;<font color='red'>36%</font>&nbsp;premarket. albeit on light volume, in response to its <a href=\"https://seekingalpha.com/pr/16907824-gemphire-announces-top-line-data-royalminus-1-phase-2b-clinical-trial-hypercholesterolemic\" target=\"_blank\">announcement </a>of positive preliminary results from a Phase 2b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02634151?term=NCT02634151&amp;phase=1&amp;rank=1\" target=\"_blank\">ROYAL-1</a>, assessing the ability of once-daily oral gemcabene for lowering low-density lipoprotein cholesterol (LDL-C) in patients not adequately controlled with statins and/or ezetimibe (Merck's Zetia).</li><li>Patients receiving 600 mg of gemcabene experienced an average reduction in LDL-C of 17.2% compared to 5.5% for placebo (p=0.0057), achieving the primary endpoint.</li><li>Investors appear concerned, however, that the treatment effect, while positive, was less than COBALT-1, <a href=\"https://seekingalpha.com/pr/16875097-gemphire-announces-top-line-data-cobaltminus-1-phase-2b-clinical-trial-hofh-patients\" target=\"_blank\">reported </a>in June. In this study, patients receiving the same 600 mg dose experienced a mean LDL-C reduction of 30% (p=0.047).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3276125-gemphires-gemcabene-successful-mid-stage-hofh-study-shares-10-percent-hours\" target=\"_blank\">Gemphire's gemcabene successful in mid-stage HoFH study; shares up 10% after hours</a> (June 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286222\" data-linked=\"Gemphire&#39;s cholesterol med gemcabene successful in mid-stage study but treatment effect less than previous trial; shares down 36% premarket\" data-tweet=\"$GEMP - Gemphire&#39;s cholesterol med gemcabene successful in mid-stage study but treatment effect less than previous trial; shares down 36% premarket https://seekingalpha.com/news/3286222-gemphires-cholesterol-med-gemcabene-successful-in-mid-stage-study-treatment-effect-less?source=tweet\" data-url=\"https://seekingalpha.com/news/3286222-gemphires-cholesterol-med-gemcabene-successful-in-mid-stage-study-treatment-effect-less\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286211\" data-ts=\"1502108971\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TIS\" target=\"_blank\">TIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286211-on-orchids-paper-products-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Orchids Paper Products&#39; Q2</a></h4><ul>     <li>Orchids Paper Products (NYSEMKT:<a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a>) reports Converted product net sales decreased 11.8% to $34.7M.</li>     <li>Parent rolls net sales was $3.75M.</li>     <li>Gross margin rate fell drastically from 17.4% year ago to 3.9%.</li>     <li>SG&amp;A expense rate expanded 220 bps to 8.6%.</li>     <li>Adjusted EBITDA margin also dropped to 6.4% vs. 20.9% in 2Q16.</li>     <li><a href=\"https://seekingalpha.com/pr/16907820-orchids-paper-products-company-announces-2017-second-quarter-results\" target=\"_blank\">Press release</a></li>      </ul><div class=\"tiny-share-widget\" data-id=\"3286211\" data-linked=\"More on Orchids Paper Products&#39; Q2\" data-tweet=\"$TIS - More on Orchids Paper Products&#39; Q2 https://seekingalpha.com/news/3286211-on-orchids-paper-products-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3286211-on-orchids-paper-products-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286209\" data-ts=\"1502108538\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LINC\" target=\"_blank\">LINC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286209-on-lincoln-educational-services-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Lincoln Educational Services&#39; Q2</a></h4><ul>     <li>Lincoln Educational Services (NASDAQ:<a href='https://seekingalpha.com/symbol/LINC' title='Lincoln Educational Services Corporation'>LINC</a>)&nbsp;reports revenue fell 9.1% in <a href=\"https://seekingalpha.com/pr/16908051-lincoln-educational-services-reports-second-quarter-results-student-starts-healthcare\" target=\"_blank\">Q2</a>, mainly due to suspension of new student enrollments at campuses in the Transitional segment.</li>     <li>Transportation and skilled trades revenue slightly up by 0.7% to $41.3M.</li>     <li>Healthcare and Other Professions revenue declined 4.3% to $17.9.</li>     <li>Transitional revenue squeezed 69% to $2.6M, mainly attributable to the closing of campuses within this segment.</li>     <li>SG&amp;A expense rate grew 500 bps to 57.5% for the period.</li>     <li>Enrolled students -1,108 Y/Y to 10,400.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3286209\" data-linked=\"More on Lincoln Educational Services&#39; Q2\" data-tweet=\"$LINC - More on Lincoln Educational Services&#39; Q2 https://seekingalpha.com/news/3286209-on-lincoln-educational-services-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3286209-on-lincoln-educational-services-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286207\" data-ts=\"1502108389\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPI\" target=\"_blank\">IPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286207-intrepid-potash-cut-to-sell-ubs-after-last-weeks-big-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intrepid Potash cut to Sell at UBS after last week&#39;s big gains</a></h4><ul>     <li>Intrepid Potash (NYSE:<a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a>) <font color='red'>-3.4%</font> premarket as UBS <a href=\"http://thefly.com/thestreet/realmoney/index.php/IPIid2591782/IPI-Intrepid-Potash-downgraded-to-Sell-from-Neutral-at-UBS\" target=\"_blank\">downgrades shares to Sell</a> from Neutral, citing valuation after jumping nearly 30% last week.</li>     <li>Although bankruptcy risk has been \"significantly reduced\" since the share count was  increased 60% with the March secondary offering, UBS says it remains concerned about the lack of long term growth in non-core income and \"still depressed\" core potash related income.</li>     <li>The firm remains cautious on potash pricing, forecasting only a modest increase in 2018, but IPI has popped recently due to a de-risked balance sheet and  optimism around a more diversified revenue stream.</li>     <li>While UBS downgrades the stock, it raises its price target for IPI shares to $2.50 from $2.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3286207\" data-linked=\"Intrepid Potash cut to Sell at UBS after last week&#39;s big gains\" data-tweet=\"$IPI - Intrepid Potash cut to Sell at UBS after last week&#39;s big gains https://seekingalpha.com/news/3286207-intrepid-potash-cut-to-sell-ubs-after-last-weeks-big-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3286207-intrepid-potash-cut-to-sell-ubs-after-last-weeks-big-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286201\" data-ts=\"1502107773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286201-fda-oks-tevas-asthma-med-qvar-redihaler-shares-down-5-premarket-sell-off-continues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Teva&#39;s asthma med QVAR RediHaler; shares down 5% premarket as sell-off continues</a></h4><ul><li>Teva Pharmaceutical Industries' (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) <a href=\"https://seekingalpha.com/pr/16908012-teva-announces-fda-approval-qvar-redihaler-beclomethasone-dipropionate-hfa-inhalation-aerosol\" target=\"_blank\">announces&nbsp;</a>that the FDA has approved its QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol for the maintenance treatment of asthma in patients at least four years old. Commercial launch should commence in Q1 2018.</li><li>Investors are still heading for the exits, however. Shares are down&nbsp;<font color='red'>5%&nbsp;</font>premarket on robust volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285160-teva-q2-top-line-13-percent-earnings-big-cash-flow-23-percent-guidance-lowered-shares-9\" target=\"_blank\">Teva Q2 top line up 13%; earnings down big; cash flow down 23%; guidance lowered; shares down 9% premarket</a> (Aug. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286201\" data-linked=\"FDA OKs Teva&#39;s asthma med QVAR RediHaler; shares down 5% premarket as sell-off continues\" data-tweet=\"$TEVA - FDA OKs Teva&#39;s asthma med QVAR RediHaler; shares down 5% premarket as sell-off continues https://seekingalpha.com/news/3286201-fda-oks-tevas-asthma-med-qvar-redihaler-shares-down-5-premarket-sell-off-continues?source=tweet\" data-url=\"https://seekingalpha.com/news/3286201-fda-oks-tevas-asthma-med-qvar-redihaler-shares-down-5-premarket-sell-off-continues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286185\" data-ts=\"1502107191\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRG\" target=\"_blank\">BRG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286185-bluerock-residential-downgraded-compass-point\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bluerock Residential downgraded at Compass Point</a></h4><ul><li>Compass Point's Steve Shaw bails on his Buy rating <a href=\"https://seekingalpha.com/pr/16907270-bluerock-residential-growth-reit-brg-announces-agreement-internalize-management\" target=\"_blank\">after Friday's news</a> about plans to internalize management and hint of a dividend cut on the way. Shares&nbsp;<font color='red'>fell 16.9%</font>&nbsp;on Friday.</li><li>Consideration to the current external manager will be $41M-$42M - nearly all to be paid in equity. Immediate cost savings of $3.8M are expected in the first year after internalization (expected shortly after the annual meeting in late October).</li><li>The board is undertaking a comprehensive review of the common stock dividend policy, hoping to achieve something sustainable by current AFFO. The review is expected to be completed in Q4.</li><li><a href='https://seekingalpha.com/symbol/BRG' title='Bluerock Residential Growth REIT, Inc.'>BRG</a> no trades premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3286185\" data-linked=\"Bluerock Residential downgraded at Compass Point\" data-tweet=\"$BRG - Bluerock Residential downgraded at Compass Point https://seekingalpha.com/news/3286185-bluerock-residential-downgraded-compass-point?source=tweet\" data-url=\"https://seekingalpha.com/news/3286185-bluerock-residential-downgraded-compass-point\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286184\" data-ts=\"1502107134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AITB\" target=\"_blank\">AITB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286184-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>AIT Therapeutics (<a href='https://seekingalpha.com/symbol/AITB' title='AIT Therapeutics, Inc.'>OTCQB:AITB</a>) initiated with Buy rating and $17 (209% upside) price target by Ladenburg Thalmann.</li><li>BeiGene (NASDAQ:<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene'>BGNE</a>) initiated with Buy rating and $81 (13% upside)&nbsp;price target by Ladenburg Thalmann.</li><li>Nektar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a>) initiated with Buy rating and $31 (55% upside) price target by H.C. Wainwright.</li><li>Zoetis (NYSE:<a href='https://seekingalpha.com/symbol/ZTS' title='Zoetis'>ZTS</a>) resumed with Neutral rating and $62 (flat) price target by Goldman Sachs.</li><li>Illumina (NASDAQ:<a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a>) upgraded to Buy with a $215 (11% upside) price target by Canaccord Genuity.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) downgraded to Underweight with a $16 (22% downside risk) price target by Morgan Stanley. Downgraded to Market Perform with a $26 (26% upside) price target by Bank of Jerusalem. Shares are down&nbsp;<font color='red'>5%</font>&nbsp;premarket on robust volume.</li><li>Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a>) downgraded to Neutral with a $4 (36% downside risk)&nbsp;price target by Cantor Fitzgerald following the failed study of ZYN002 in epilepsy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286184\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$AITB $XAIR $BGNE - Premarket analyst action - healthcare https://seekingalpha.com/news/3286184-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3286184-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286181\" data-ts=\"1502106520\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZYNE\" target=\"_blank\">ZYNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286181-zynerbas-zyn002-flunks-mid-stage-epilepsy-study-shares-down-48-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zynerba&#39;s ZYN002 flunks mid-stage epilepsy study; shares down 48% premarket</a></h4><ul><li>Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a>) <a href=\"https://seekingalpha.com/pr/16907847-zynerba-pharmaceuticals-announces-top-line-results-phase-2-star-1-trial-zyn002-adult-epilepsy\" target=\"_blank\">announces </a>that its Phase 2 clinical trial, STAR 1, assessing co-lead product candidate ZYN002 (cannabidiol [CBD] gel) in adult epilepsy patients with focal seizures failed to beat placebo as measured by a statistically valid reduction in seizures compared to baseline.</li><li>STAR 1 randomized 188 patients to receive either 97.5 mg of ZYN002, 195 mg of ZYN002 or placebo every 12 hours for 12 weeks.</li><li>Patients in the low-dose cohort experienced an 18.4% median reduction in focal seizures compared to baseline. The high-dose group and placebo showed 14.0% and 8.7% median reductions, respectively.</li><li>On the plus side, ZYN002 was safe and well-tolerated.</li><li>The company is also evaluating ZYN002 in osteoarthritis and Fragile X syndrome.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li><li>Shares are down&nbsp;<font color='red'>48%</font>&nbsp;premarket on robust volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3250568-zynerba-completes-enrollment-two-mid-stage-studies-co-lead-product-candidate-zyn002\" target=\"_blank\">Zynerba completes enrollment in two mid-stage studies of co-lead product candidate ZYN002</a> (March 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3286181\" data-linked=\"Zynerba&#39;s ZYN002 flunks mid-stage epilepsy study; shares down 48% premarket\" data-tweet=\"$ZYNE - Zynerba&#39;s ZYN002 flunks mid-stage epilepsy study; shares down 48% premarket https://seekingalpha.com/news/3286181-zynerbas-zyn002-flunks-mid-stage-epilepsy-study-shares-down-48-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3286181-zynerbas-zyn002-flunks-mid-stage-epilepsy-study-shares-down-48-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3286168\" data-ts=\"1502105649\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOK\" target=\"_blank\">MYOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3286168-myokardia-q2-reveneus-up-60-shares-ahead-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MyoKardia Q2 reveneus up 60%; shares ahead 17% premarket</a></h4><ul><li>MyoKardia (<a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a>) <a href=\"https://seekingalpha.com/pr/16907931-myokardia-reports-second-quarter-2017-financial-results-operational-progress\" target=\"_blank\">Q2 results</a>: Revenues: $5.6M (+60.0%); Operating Loss: ($13.1M) (-33.7%); Net Loss: ($12.8M) (-30.6%); Loss Per Share: ($0.41) (-10.8%); Quick Assets: $133.3M (-4.7%).</li><li>No guidance given.</li><li>Shares are up&nbsp;<font color='green'>17%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3286168\" data-linked=\"MyoKardia Q2 reveneus up 60%; shares ahead 17% premarket\" data-tweet=\"$MYOK - MyoKardia Q2 reveneus up 60%; shares ahead 17% premarket https://seekingalpha.com/news/3286168-myokardia-q2-reveneus-up-60-shares-ahead-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3286168-myokardia-q2-reveneus-up-60-shares-ahead-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:34 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}